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In Type 1 diabetic (T1D) patients, it is crucial to keep the blood 
glucose (BG) concentration in normoglycemic region (70~126mg/dL) in 
fasting condition and under 180mg/dL in postprandial condition using 
exogenous insulin infusion. Such regulation is important in order to avoid 
hyperglycemia (blood glucose values that are above normoglycemic region) 
and its long term impact on the diabetics (complications such as nephropathy 
and retinopathy) and dangerous hypoglycemia (blood glucose values that are 
below normoglycemic region) that leads to diabetic coma and possibly death 
on a short-term basis. 
A number of mathematical models that represent T1D patients and 
control algorithms for blood glucose regulation in diabetic patients have been 
developed in the literature. These control algorithms were also shown to cope 
well with inter- and intra-patient variability. The aim of this research is to find 
efficient and practically implementable control algorithms by employing some 
state of the art diabetic models (that accurately simulate the diabetes patient) 
for effective regulation of blood glucose. This thesis also seeks to extend the 
utility of simple dynamic protocols that are currently practiced for treating 
hyperglycemia in patients admitted to critical/intensive care units to treat T1D 
patients. For this purpose, the Yale insulin Infusion Protocol (YIIP) is 
implemented and studied on different T1D “patients”. Studies indicate that the 
YIIP can be tailored and used for effective BG regulation in T1D “patients”. 
The thesis also examines if the “patients” can be classified into different 
groups and subject to class-specific tailored algorithms. To achieve this 
objective, a simple diabetes diagnostic test (Intravenous Glucose Tolerance 
Test, IVGTT) and a multivariate statistical tool (Principal Component 
Analysis, PCA) are utilized. Then, YIIP is tailored to work for different 
patient classes. Applicability of this investigation through validation on 
different patient models is also attempted. The results show that the developed 
algorithm can be very useful for BG control in T1D patients.   
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For the purpose of this thesis, the modeling error compensator 
(controller) based on a linear reference model (LMEC) is considered and 
evaluated on three diabetic models. The results demonstrate that the LMEC 
controller is a good candidate for controlling diabetes. The BG control is more 
effective with the patient-specific T1D patient model which could be 
constructed from past data collected from the patient. Multirate system 
identification (MRID) may be quite handy in this regard. Frequent sampling of 
BG concentration is also required for effective control but the current glucose 
sensor technology has its own limitations. In healthy humans, the endogenous 
insulin response to the BG changes within seconds. The BG control would be 
more effective if the control algorithm can mimic the healthy human 
physiological response. To achieve this goal, the availability of frequent BG 
measurement is a key factor. To solve this problem, a LMEC algorithm with 
36 seconds control interval and 3 minute BG concentration sampling interval 
with estimation of intersample BG measurement using models obtained from 
MRID is developed. Using simulated data, this idea is shown to be applicable 
and extendable to situations with larger BG concentration sampling intervals. 
The developed schemes are expected to be useful in advancing the goal 
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1.1 Homeostasis and Blood Glucose Regulation 
Homeostasis is the term describing the self-regulation of the process or 
activities in a biological or mechanical system to maintain stability of the 
internal environment by adjusting to changing conditions (Wikipedia, 2009b). 
It is vital to keep human body in homeostasis such as body temperature 
regulation, blood glucose (BG) regulation and hormonal regulation. The 
regulation of blood glucose to maintain glycemia (the concentration of glucose 
in the blood) in normal range is an important aspect of metabolic homeostasis. 
The mean normal glycemic value for healthy human is 90mg/dL or 5mmol/L. 
Glucose is the main source of energy for the body and brain and it is enriched 
mainly from consumed sugar and carbohydrate. BG level rises up mainly due 
to food intake and is also influenced internally by stress hormones, steroids, 
cortisone, growth hormones etc. BG is lowered by prolonged and intensive 
physical exercise and reduction/lack of nutrition.  
BG is continuously regulated by insulin and glucagon. Glucagon is 
released from alpha cells of pancreas when BG level is low. Glucagon 
stimulates breakdown of glycogen stored in liver (glycogenolysis). The 
glycogenolysis produces glucose from stored glycogen which gets introduced 
into the blood stream to raise BG level. Conversely, insulin is produced from 
the beta cells of pancreas when BG rises up to higher level either due to meal 
consumption or through glycogenolysis. Insulin activates conversion of 
glucose into glycogen to be stored in liver (and in muscle) by glycogenesis and 
helps muscle and adipose tissues to take glucose from blood for their 
metabolism. Thus BG level is lowered. With these mechanisms, glycemic 
homeostasis is maintained by the presence of these two hormones (glucagon 
and insulin) in healthy individuals. When these mechanisms are impaired over 




There are two main types of diabetes: Type 1 and Type 2 diabetes. 
Type 1 Diabetes Mellitus (T1D) is caused by inadequate insulin production 
due to beta cell dysfunction of the pancreas. The body’s inability to respond 
properly to endogenous insulin because of insulin resistance or decreased 
insulin sensitivity with or without insufficient endogenous insulin is classified 
as Type 2 Diabetes Mellitus (T2DM). The type of diabetes that can occur in 
women during pregnancy period is known as gestational diabetes, and another 
type of glucose impairment can happen to critically ill patients or patients in 
ICU (intensive care unit) temporarily because of hyperglycemia. 
 
1.2 Diabetes and Glycemic Regulation 
The complete lack or insufficient amount of endogenous insulin for an 
extended period of time causes diabetes. Diabetes is a metabolic disorder that 
affects the body’s ability to regulate glucose concentration in blood resulting 
in high or low BG concentration. In T1D, improper metabolic response to 
glucose (with or without inadequate insulin production by the pancreas) can 
cause the supranormal plasma glucose concentration. T1D patients’ response 
to insulin is normal without loss of insulin sensitivity. This is also known as 
insulin dependent diabetes mellitus (IDDM). In T2DM, also known as non-
insulin dependent diabetes mellitus (NIDDM), in which the very high BG 
values are a result of insulin resistance. In the gestational diabetes, pancreas 
can produce normal insulin but it cannot produce extra insulin to counteract 
the interfering effect of other hormones produced by placenta (placenta is to 
provide nutrition from mother to the embryo) and the pancreas does not have 
persistent malfunction. These hormones hinder the body ability to respond 
insulin properly and it causes insulin resistance and thus hyperglycemia. The 
critically ill patients or patients in ICU experience stress induced 
hyperglycemia even if they do not have any past history of diabetes. Other 
factors such as presence of hypertension, cortisone, steroids and pancreatic 
disease also results in hyperglycemia.  
      High BG value results in excessively sweet urine (glycosuria) as the 
renal clearance (kidney excretes plasma glucose into urine) starts when BG is 
3 
 
above 190~200mg/dL (also known as renal threshold). It leads to polyuria 
(frequent urination) and polydipsia (increased thirst) and these are well-known 
common symptoms of diabetes. It can lead to the cell dehydration, and the 
increased fluid intake only cannot cure the disease because the whole 
mechanism is regulated with the hormones and other mechanisms and thus 
medication is needed. For Type 1 diabetes, external insulin is required to 
regulate the BG regulation mechanism because of inadequate endogenous 
insulin. For Type 2 diabetes, a variety of medication, dietary changes and 
exercise are suggested to improve insulin sensitivity. However, if the 
medication only cannot lower the very high BG value, external insulin may be 
required for such patients. The same treatment as in T2D is required for the 
treatment of gestational diabetes and sometimes external insulin is required to 
lower the BG level. The intensive insulin infusion is suggested for the control 
of hyperglycemia in ICU patients. 
This thesis focuses on the control of BG concentration in Type 1 
diabetes. Type 1 diabetes and glycemic control are discussed further in the 
next section. 
 
1.3 Type 1 Diabetes and Glycemic Control 
T1D is an autoimmune disease defect in pancreas and can happen in 
both children and in adults. In the pancreas (specifically in the insulin 
producing beta cells) of those patients, T-cells mediated autoimmune attack by 
the virus destroyed the pancreatic beta cells and thus pancreas is unable to 
produce any or sufficient insulin (Wikipedia, 2009a).  Exogenous insulin is 
needed by continuous infusion and/or by bolus for controlling plasma glucose 
concentration to the levels seen in healthy individuals (70~126mg/dL 
(=3.9~7mmol/L) in fasting condition and slightly upward levels, 140mg/dL 
(7.6mmol/L) is expected 2 hours after meals). If insulin is supplied in excess, 
BG concentration would go below normal (<70mg/dL), and results in a 
condition known as hypoglycemia. The healthy individuals start suffering the 
symptoms of hypoglycemia when BG goes below 55mg/dL (3mmol/L).  On 
the other hand, if not enough insulin is supplied, the blood glucose 
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concentration would elevate and persistently stay beyond 180mg/dL 
(10mmol/L) resulting in a condition known as hyperglycemia. Both hypo- and 
hyper-glycemia can be harmful to an individual’s health. The effects of 
hypoglycemia are critical on short-term basis, and can lead to diabetic coma 
and possibly death. If insulin amount is very low or insufficient, the 
breakdown of fatty acids and amino acids occurs and it can lead to 
ketoacidosis. Sustained hyperglycemia can result in the long-term 
complications including microvascular diseases such as nephropathy, 
retinopathy, other tissues damage, and macrovascular diseases such as 
coronary heart disease, cerebrovascular disease, peripheral vascular disease 
and neuropathy. 
According to the Diabetes Control and Complications Trial (DCCT) 
(DCCT, 1993), BG should be controlled as close as possible to the normal 
range. DCCT set the intensive goal of maintaining BG concentration within 
70~120mg/dL pre-meal condition and less than 180mg/dL in post-meal 
condition. It was found that setting intensive goal can lower the rate of 
microvascular complications in diabetes patients. The American Diabetes 
Association (American Diabetes Association, 2006) recommends maintaining 
BG level between 90~130mg/dL (5~7.2mmol/L) in preprandial condition and 
less a 180mg/dL (10mmol/L) in postprandial condition.  
For T1D patients, self-management is required to adjust the insulin 
according to their BG level so as to regulate BG as closely as possible to 
mimic the profile seen in healthy individuals. To do this round the clock and in 
an effective manner, automatic closed loop control has been acknowledged as 
the best choice. For this purpose, various mathematical models have been 
developed to represent the glucose dynamics in type I diabetics. Several 
control algorithms have also been proposed to control the BG level within the 
acceptable range. While some of these works have been evaluated in clinical 
trials, many are not. Accurate quantification and understanding of BG 
dynamics (in relation to infused insulin, meals, exercise and other 
disturbances) in the form of a mathematical model is crucial in achieving 
tighter glucose regulation through automatic control schemes.  
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To cope with different patient characteristics as well as time-varying 
characteristics in any particular patient, advanced strategies would be required. 
On the hardware front, glycemic control is still limited by the infrequent 
nature of glucose sensing but rapid improvements have happened in this front 
recently (Oliver et al., 2009). The vaccine and stem cell replacement are in 
investigations and are not fully resolved the problems till date. The effective 
control of the diabetes patient should lead to a titration where the glucose 
regulation mimics the healthy person’s response. This can be achieved by 
developing a control algorithm that can cope well with the inter- and intra-
patient variability, various situations of a patient such as exercise, anxiety, 
sickness and the constraints on insulin infusion rate and frequency of BG 
concentration measurement.  
      Before going into the motivation and scope of the present work, let us 
take a quick look at insulin action and insulin analogs in Section 1.4. 
 
1.4 Insulin Action and Insulin Analogues 
Insulin plays an important role in our body metabolism. Endogenous 
insulin (pancreatic insulin) is continuously regulated in the circulation and it 
changes according to the BG concentration within seconds. It is secreted into 
circulation through portal vein and about 40% to 80% is utilized by the liver. 
Then it is diluted into the systemic insulin pool (Young and Koda-Kimble, 
2000; Pørksen, 2002), and is diffused as unbound (free insulin) in plasma. In 
glucose regulation, insulin binds the receptor on the cell wall and translocates 
the vesicles containing GLUT-4 (glucose transporter 4) to the plasma 
membrane where the diffusion of the glucose (and amino acid) to the cell takes 
place. Then it activates the glycogenesis (glycogen synthesis) in peripheral and 
adipose tissue, glycolysis, fatty acid synthesis and esterification.  It promotes 
DNA replication and protein synthesis in the body. It decreases the undesired 
proteolysis (hydrolytic breakdown of proteins), lipolysis (hydrolysis of lipids), 
gluconeogenesis (the formation of glucose from non-carbohydrate sources) 
and autophagy (self-digestion by a cell within the same cell by enzymes). In 
addition, it facilitates the arterial blood flow by relaxing the arterial wall 
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muscle. If insulin is lacking, the blood flow will be reduced because of muscle 
contraction. After binding the receptor and effected its actions, insulin is 
degraded by the insulin degrading enzyme and by liver cells or is released 
back to the extracellular compartment. The endogenous insulin degrades 
within approximately one hour after entering into circulation.   
      For the benefit of people who lack adequate endogenous insulin, there 
are many insulin analogs produced by synthetic routes. These analogs can 
function in place of endogenous insulin and provide glycemic control. They 
are injected or infused exogenously by means of intraperitoneal (i.p) or 
subcutaneous (s.c) or intravenous (i.v) or intramuscular (i.m) routes which are 
all invasive. They can be administered non-invasively through oral, nasal, 
pulmonary or transdermal membrane. The short-acting insulin or rapid-acting 
insulin such as insulin lispro contains monomers and dimers and are soluble 
more rapidly after injection. Some exogenous insulin analogs are made with 
hexamer molecules and must undergo dissociation into absorbable dimers and 
monomers at the injection sites such as regular insulin. The long-acting insulin 
such as NPH starts its action more slowly than soluble insulin but its effect 
lasts for longer.  
The exogenous insulin delivery is affected by external factors such as 
mode of insulin infusion (routes) and type of insulin. The exogenous insulin is 
degraded at liver, muscle and mostly at the kidney (30~80%). Insulin infusion 
is also the only one therapy that is currently used to control diabetes in ICU 
patients. According to the literature, tight glucose control effected via 
exogenous insulin infusion can reduce ICU patient mortality by as much as 
43% (Van den Berghe, 2003). 
 
1.5 Motivation for and Scope of the Present Work 
This work is motivated by the fact that lowering BG for hyperglycemia 
prone patients reduces the risk of eye disease, kidney failure and nerve disease 
by 76%, 50% and 60% respectively (DCCT, 1993). It has been noted by 
Boutayeb and Chetouani (2006) that a study involving over 5000 non-insulin 
dependent patients from 23 centers from all parts of England, Scotland and 
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Northern Ireland showed that complications of diabetes can be prevented by 
better control of BG and blood pressure. 
The variability in glucose metabolism, insulin sensitivity, effects of 
other medical conditions are quite large among different patients and within 
the same patient (over time) leading to inter- and intra-patient variability. No 
single control algorithm may be able to handle such large uncertainties and it 
may be useful to classify patients into appropriate classes and apply tailored 
control algorithms to each of the classes. The classification should possibly be 
done with a simple diagnostic test. It would be worthwhile to develop a 
control scheme that is tailored to different patients groups where the patient 
“group” can be described using a simple diagnostic test.  
The insulin infusion rate can be measured more frequently than the 
measurement of BG leading to a multirate system. Glucose sensor technology 
is still in development and we are unable to monitor the BG as frequently as 
we are able to measure insulin infusion rate. It would be interesting to obtain a 
fast-rate model from multirate patient data. The fast-rate model will ensure 
better control of the BG level by frequent manipulation of insulin infusion. 
The main objectives of this work are to develop effective control 
algorithms for blood glucose level regulation in type 1 diabetic patients. These 
algorithms must cope well with the inter- and intra-patient variability. The 
control algorithms studied here include simple protocol based control, tailored 
protocol based control with patient classification into sub-groups, linear robust 
controller and linear robust multirate control. With these objectives, the 
organization of the thesis is presented next. 
 
1.6 Organization of the Thesis 
      A review of mathematical models developed for T1D patients and the 
controller algorithms that are currently employed for controlling BG 
concentration and other related topics are discussed in Chapter 2. The unique 
properties of the three chosen diabetes models and the generation of several 
simulated patients from these three models are described in Chapter 2 also. 
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Introduction and application of a current hospital protocol (Yale Insulin 
Infusion Protocol, YIIP) to a cohort of diabetes patients forms the substance of 
Chapter 3. The classification of patients using the method of principal 
component analysis (PCA) to data collected from a diagnostic test and 
tailoring of YIIP for the different patient classes are described in Chapter 4. 
Validation of the above methodology with other patient models is also 
demonstrated in Chapter 4. Evaluation of a robust linear controller (LMEC) 
that can handle the parametric uncertainty explicitly in the three different 
models and on several simulated “perturbed” patients is demonstrated in 
Chapter 5. Use of multirate system identification in conjunction with LMEC 
controller to diabetic patient models (i.e., developing a new algorithm that 
uses multirate data and multirate system identification and the resulted 
identified model is used in a linear controller to regulate glucose levels in 
diabetic patients with more frequent sampling interval in seconds which is 
closely compatible to human physiological system) is described in Chapter 6. 
Finally, the conclusions of this research study and proposed future works are 




Modeling and Glycemic Control in Type 1 Diabetes Patients 
 
 To achieve effective BG control in T1D patients, the artificial pancreas 
has been proposed (Hovorka et al., 2006). The artificial pancreas involves a 
continuous glucose sensor to measure the patient’s blood glucose (BG), a 
control algorithm that uses this BG measurement and the target blood glucose 
value (set point) to determine the appropriate rate of insulin dosage, and an 
insulin infusion pump to deliver the exact amount of exogenous insulin via the 
subcutaneous or intravenous route. A review of electrochemical glucose 
sensors and their application in diabetes management is available in the recent 
literature (Heller and Feldman, 2008). Current progress in glucose sensor 
technology is reviewed by Oliver et al. (2009). Insulin pump systems that can 
store and precisely infuse the required amount of insulin automatically are 
now available in the market. Currently available insulin pumps, continuous 
glucose monitoring and the requirement to integrate these systems into closed-
loop control are reviewed by Aye et al. (2010).  The focus of this chapter is 
not on the hardware components of the artificial pancreas system but on the 
soft components such as the mathematical models and the control algorithms 
employed for BG control in TID patients.  
 
2.1 Mathematical Models 
 For advanced control applications, a mathematical model that 
represents the behavior of the physical system as closely as possible is very 
vital. Mathematical models of biomedical systems are applicable for other 
purposes such as in silico diagnostics test and development and testing of 
treatment regime (Zheng et al., 2007). Many mathematical models describing 
the effects of insulin and glucose intake on blood glucose concentration in 
type 1 diabetes patients have been developed and reported in the literature. 
These T1D models mainly involve the glucose subsystem, insulin subsystem 
and/ or meal subsystem. These models do not involve any term(s) related to 
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endogenous insulin secretion; instead, the pharmacodynamics/ 
pharmacokinetics of exogenous insulin are involved. In addition to 
phenomenological models, data-driven models are also available. The latter 
models are usually obtained based on the best parameter fit to patient data with 
well-known model structures such as the first order plus time delay structure 
or one of the standard time series models (autoregressive with exogeneous 
inputs (ARX), autoregressive moving average with exogeneous inputs 
(ARMAX), output error (OE), Box-Jenkins (BJ) etc.).  Hybrid models that 
combine the above two model classes are also in vogue. Section 2.1.1 
describes some T1D models that are popular in the literature and section 2.1.2 
familiarizes the reader with some of the commonly employed meal 
disturbance models.  
 
2.1.1 Models for T1D Patients 
The first diabetes model was proposed by Bolie in 1961 (Bolie, 1961) 
and another one was proposed shortly thereafter by Ackerman et al. (1965). 
The models developed since then can be classified into metabolic species (e.g., 
glucose, insulin)-based compartmental model and organ-based compartmental 
models. In the former type of model, the whole body is represented by 
compartments (e.g., glucose compartment, insulin compartment) and the 
metabolic species in each compartment is assumed to be homogeneous. In 
organ-based compartmental models, each major organ is represented as a 
compartment and metabolic-species balances are written for each 
compartment. The organ-based compartmental models are in general more 
detailed than the metabolic species-based compartmental models and 
consequently involve more parameters.  
Compartmental modeling started with the work of Bergman et al. 
(1981) whose model has come to be known as the ‘minimal’ model. 
Bergman’s model includes glucose and insulin interaction terms so that it 
acknowledges that glucose changes are effected by insulin. The nonlinearity of 
the glucose dynamics in the minimal model is found to closely reflect the true 
human glucose metabolism. Insulin effects on liver and periphery glucose 
utilization are modeled as constant terms, and they affect both insulin 
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appearance and disappearance in the remote insulin compartment. The delay 
of insulin action and other complex phenomena are lumped in a remote 
compartment. Glucose effectiveness and insulin sensitivity index (ISI) can be 
estimated from the parameters of this model. It is to be noted that the ISI 
indicates how the BG glucose responds to insulin - a very low ISI means a 
very high resistance to insulin. Generally, high ISI is desirable for controlling 
the BG level.  
Cobelli et al. (1982) incorporated the nonlinear nature of glucose, 
glucagon and insulin compartments (model for insulin compartment is built 
based on the pancreatic function) using suitable nonlinear ordinary differential 
equations. The distinct feature of this model is that it takes into consideration 
the glucagon effect. This work marked the start of inclusion of glucagon effect 
into diabetic patient models and led to more comprehensive models (beyond 
the minimal model). The model by Cobelli et al. is also based on mass balance 
of each metabolic species and physiological knowledge of human body with 
threshold functions for biological pools. This model was mainly developed for 
intravenous glucose infusion and intravenous glucose tolerance test (IVGTT) 
(Dalla Man et al., 2007).  
The model developed by Hovorka et al. (2002) is an extension of the 
minimal model but insulin action on glucose distribution/transport, disposal 
and production are differentiated. In a later work by Hovorka et al. (2004), the 
model was improved to enable direct access of plasma insulin concentration. 
In their earlier model, only the remote insulin compartment was accessible. 
These two models are based on mass balances based on the physiological 
knowledge prevalent at the time. Hovorka et al. (2002) took nonaccessible 
compartment of both insulin and glucose as well as meal digestion into 
consideration. Wilinska et al. (2005) further modified the subcutaneous insulin 
infusion mode of this model by including fast and slow insulin absorption 
channels and local insulin degradation – this enables the study of glycemic 
control via subcutaneous insulin infusion. However, the incorporated 
intrapatient variability in this model may need to be improved further 
(Wilinska and Hovorka, 2009). 
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Fabietti et al. (2006) developed a model for type 1 diabetes in which 
exogenous insulin infusion can be administered through intravenous or 
subcutaneous route. This model can also be regarded as an extension of the 
minimal model. Because an interstitial compartment is included, the interstitial 
glucose concentration is available for this model. The model includes a term 
for renal clearance and another term for intravenous glucose infusion. This 
makes the model convenient for simulating intravenous glucose tolerance test 
(IVGTT). This model is also compatible with subcutaneous glucose sensor and 
subcutaneous insulin infusion device. In addition, the well-known circadian 
insulin sensitivity variation is accounted for and the model can therefore 
represent the dawn phenomena (elevation of blood glucose concentration in 
the morning hours) commonly experienced by diabetic patients. In addition, 
the more reasonable mixed meal model according to Arleth et al. (2000a, 
2000b) is implemented.  
Another type of organ-based compartmental modeling was described 
by Parker et al. (2000). They developed a more detailed diabetes model - a 
19th order model characterized by nonlinear differential equations based on 
physiological knowledge and the work of Sorensen (1985). In this model, the 
human body is divided into six compartments. Glucose, insulin balance and 
kinetics are modeled by ordinary differential equations describing the nature 
of the interactions between them. This model also includes the effect of 
glucagon and employs threshold functions for hepatic glucose production, 
hepatic glucose uptake, peripheral glucose uptake, and kidney clearance. The 
model contains 47 physiological parameters making it less amenable for 
parameter estimation and controller design (for artificial pancreas) but is more 
comprehensive (while not necessarily more accurate) than many other models 
available in the open literature.  
The most comprehensive model of the biochemical pathophysiological 
processes associated with type 1 diabetes mellitus would be the Archimedes 
diabetes model elaborated by Eddy and Schlessinger (2003a). This model 
consists of a network of interrelated variables including biological (mechanism 
of diabetes), clinical and administrative details linked by differential equations 
describing the nature of the interactions among the variables. The biological 
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variables used and the relation between them are selected by the investigators 
based on the current knowledge of biological systems. It includes severity of 
symptoms and the presence of vascular complications. The full Archimedes 
model includes the important factors of real health care system including 
health care personnel, facilities, equipment, supplies, policies and procedures, 
regulations, utilities and cost. According to Eddy and Schlessinger (2003b), 
simulation of a clinical trial takes about 10 min using 250 PCs with this model. 
It can be concluded that this model is computationally burdensome. The 
clinical validation of this model gives statistically insignificant results 
compared with clinical outcomes (Boutayeb and Chetouani, 2006). The 
limitations of this model are that the functional forms of the equations are 
given but values of the variables and parts of the model for micro and macro-
vascular complication are not provided in the open literature. 
 
2.1.2 Meal Disturbance Models in Diabetes Patient Models 
 Inclusion of a suitable meal ingestion model to the model describing 
the glucose and insulin dynamics is essential for any meaningful studies to be 
conducted on the in silico diabetes patient model. In this section, the intention 
is to provide a description on the most commonly utilized meal models. The 
mathematical description of these meal models are presented with their 
associated T1D model in section 2.3.  
The meal model of Fisher (1991) is modeled for glucose only and used 
an exponential function to represent the glucose appearance in glucose 
compartment from gut absorption for normal subjects. Such modeling is more 
suitable for glucose clamps such as oral glucose tolerance test (OGTT) and is 
mostly associated with Bergman’s minimal model. The meal model of 
Lehmann and Deutsch (1992) is built with trapezoidal functions and reflects 
the saturation of gut absorption rate. It is also modeled for pure carbohydrate 
(CHO), and has been mostly used in their later studies and by Parker et al. 
(1999). Hovorka et al. (2002) employed their own meal model, which includes 
exponential decay function (to represent the decay after the time-of-maximum 
glucose appearance rate in the accessible glucose compartment) and two 
identical transfer rates representing two-compartment chain. The innovation of 
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this model is the inclusion of bioavailability of ingested carbohydrate. The 
meal models of both Lehmann and Deutsch (1992) and Hovorka et al. (2002) 
were validated on the plasma glucose concentration and involved 
physiological refinement (Dalla Man et al., 2007).  
Arleth et al. (2000b) developed a mixed meal (presence of different 
nutrients) model for glucose absorption from ingested meal (with variable 
rate). Arleth et al. (2000a, b) modeled the ingested meal with three 
subcategories of carbohydrates viz. sugar, fast absorption starch and slow 
absorption starch with different absorption rates. This model is more realistic, 
and is used by Fabietti et al. (2006) in their diabetic patient model.  
Different meal models can account for inter-patient variation. Thus, the 
T1D model developed by Fabietti et al. (2006) (with Arleth et al, 2000a & 
2000b meal model) will be used primarily, and other Type 1 diabetic models 
with their associated meal models will be employed where necessary.   
 
2.2 Uncertainty Issues in Diabetes Patient Models 
The diabetes patients themselves are associated with many 
uncertainties such as the well-known intraday circadian insulin sensitivity, 
illness, stress experienced by them, presence of growth hormones and 
cortisone, extent of exercise etc.; all of these are considered as intra-patient 
variability. The differences between diabetes patients such as those based on 
race, age, region, eating habits, life style, insulin sensitivity, rate of insulin 
transportation, utilization & disposal, severity of the disease, and presence and 
complications arising out of other diseases all contribute to inter-patient 
variability. In addition, most of the developed diabetic patient models 
represent the nominal (average) patient and consequently are associated with 
the patient-model mismatch (i.e., the difference between the actual patient and 
the model).  
These variations can be described using uncertainty bounds in 
respective parameters for a cohort of patients. The bounds for the parameters 
that vary can be obtained from the literature or can be assumed to be within a 
15 
 
certain percentage of their nominal values. For example, Parker et al. (2000) 
considered parameters in their model to vary anywhere in the range of ±40% 
(for some parameters) or ±20% (for other parameters) from their nominal 
values. This range also ensured non-negative metabolic response of the model 
equations to standard meal inputs. The set of highly sensitive parameters is 
chosen using parametric sensitivity analysis. The cohort of virtual patients for 
control performance studies are then obtained by employing different 
combinations of the highly sensitive parameters within their range (Parker et 
al., 2000; Ramprasad et al., 2004). 
 
2.3 Chosen Diabetes Patient Models and Associated Meal Models  
From the various diabetes patient models available in the literature, the 
3rd order nonlinear ODE model of Bergman et al. (1981), the 19th order 
nonlinear ODE model of Parker et al. (2000), and the 5th order nonlinear ODE 
model of Fabietti et al. (2006) are chosen for this study. The models and the 
reasons for choosing them are described below. 
 
2.3.1 Bergman model 
Bergman’s minimal model is chosen for its simplicity (few states) and 
because it has a very small number of parameters. The original model 
parameters were obtained from the data collected on healthy subjects. To 
mimic the response characteristics of diabetes patients, Lam et al. (2002) used 
different parameter values (p1 = 0, p2 = 0.025, p3 = 0.000013).  The parameter 
representing the endogenous insulin secretion (p1) is set equal to 0 because 
there is no endogenous insulin secretion in T1D patients. The other approach 
by Lynch and Bequette (2002) estimates the parameters of the diabetic 
minimal model by fitting the responses of the Parker et al.’s diabetes patient 
model (1999a). The parameter values obtained by this approach are used in 
this study.  
Glucose compartment:       )()(1 tPGGXGpG B ++−−=                     (2.3.1.1) 
Insulin compartment:        IB VtuIInI /)()( ++−=                                (2.3.1.2) 
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Insulin remote compartment that lumps delays and other complexities is 
modeled as: 
                                   IpXpX 32 +−=                                               (2.3.1.3) 
where, 
G = concentration of the plasma glucose above the basal level (mmol/L) 
BG = basal level for plasma glucose concentration (mmol/L), (= 4.5 mmol/L  
        typically) 
X = utilization effect of insulin in a remote compartment (min-1) 
I = concentration of the plasma insulin above basal level (mU/L) 
BI = basal level for plasma insulin concentration (mU/L), (= 15 mU/L  
        typically) 
)(tP = exogenous glucose infusion rate (mmol/L/min) 
)(tu = exogenous insulin infusion rate (mU/L/min) 
21 ,, ppn = subject dependent model parameters (min
-1) (5/54 min-1, 0.028735  
                min-1, 0.028344 min-1 respectively) 
3p = subject dependent model parameter (L/mU/min
2), (5.035×105L/mU/min2) 
IV = insulin distribution volume (L), (12 L) 
 
Fisher Meal Model 
The Fisher meal model is closely associated with the Bergman model.  
The exogenous glucose infusion rate )(tP is replaced by a term representing 
the Fisher meal model. The original idea of constructing this model is to 
represent the oral glucose test of a normal subject in which BG rises up to the 
maximum glucose peak after 30 min of food intake and then falls to the basal 
level within 2 to 3 hours. For this reason, the exponential function is used with 
the model parameter values that can represent the above mentioned behavior 
of glucose appearance rate from gut absorption (Fisher, 1991).  
( )( ) , 0ktP t e tβ −= ≥                                 (2.3.1.4) 
where, 
β  = 0.5 and k  = 0.05. 
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2.3.2 Parker Model 
This model is based on the work of Sorensen (1985) and comprises of 
19 ordinary differential equations. The equations and nominal values of 
parameters are listed in Table 1. The key parameters and their uncertainty 
range have been provided in Parker et al. (2000). The meal disturbance model 
of Lehmann and Deutsch (1992) is incorporated into their model. The model 
(Parker et al., 2000) has been shown to accurately model the glucose dynamics 
of a healthy subject; their model can be simulated with null pancreatic secreted 
insulin to mimic a diabetic patient but has its shortcomings as pointed out by 
Farmer et al. (2009). The Parker model shows only small excursions in blood 
glucose values even for a significant glucose meal challenge. This makes it 
easy to control the “Parker” patient with proportional only control (Farmer et 
al., 2009) or by Proportional Derivative controllers (Ramprasad et al. 2004). 
Despite this shortcoming, we chose to study the performance of our developed 
algorithms on this model because it can represent certain patient population. 
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                           (subscript P denotes periphery (muscle/adipose tissue)) 
                                     (superscript C denotes capillary space) 
















vGk = . 
The metabolic source and sink terms (ΓI mg/min) in the above equations are: 
70BU =Γ                                                            (2.3.2.9) 
10RBCU =Γ                                                  (2.3.2.10) 
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PGU −+=Γ       (2.3.2.18) 
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HLCLC Γ++=Γ                                (2.3.2.26) 
     0PIR =Γ , as there is no pancreatic insulin release                           (2.3.2.27)
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F)N(N −Γ=                                        (2.3.2.30) 















        (2.3.2.31) 
 
The above model consists of 47 physiological parameters: values of 35 
parameters are given in Table 2.1, those of 8 other parameters in Table 2.2 and 





Table 2.1: Parameter Values in Parker et al.’s (2000) Diabetic Patient Model 
 
C
Bv =3.5 dL Bq =5.9 L/min BT =2.1 min 
T
Bv =4.5 dL   
C
Hv =13.8 dL Hq =43.7 L/min  
C
Sv =11.2 dL Sq =10.1 L/min  
C
Lv =25.1 dL Lq =12.6 L/min  
 Aq =2.5 L/min  
C
Kv =6.6 dL Kq =10.1 L/min  
C
Pv =10.4 dL Pq =15.1 L/min 
G
PT =5.0 min 
T
Pv =63.0 L   
C
BV =0.265 L BQ =0.45 L/min  
C
HV =0.985 L HQ =3.12 L/min  
C
SV =0.945 L SQ =0.72 L/min  
C
LV =1.14 L LQ =0.9 L/min  
 AQ =0.18 L/min  
C
KV =0.505 L KQ =0.72 L/min  
C
PV =0.735 L PQ =1.05 L/min 
I
PT =20 min 
T
PV =6.3 L   
NV =9.93 L PNCF =0.910 L/min FKC =0.3 
 
 
Table 2.2: Nominal Values for Uncertain Parameters in Parker et al.’s (2000) 
Diabetic Patient Model 
 
EIPGU-EГ = 1.0 EGHGU-EГ = 1.0 EGHGP-E Г = 1.0 
EIPGU-D Г = -5.82113 EGHGU-D Г = -1.48 EGHGP-D Г = -0.4969 
FHIC (FLC) = 0.4 FPIC (FPC) = 0.15  
 
 
Lehmann and Deutsch Meal Model 
Lehmann and Deutsch (1992) modeled the gut glucose absorption from 
meal taken by the T1D patients. This model considered the saturation of 
gastric emptying rate of carbohydrates from the stomach during intestinal 
adsorption. The shape of the curve depends on the consumed carbohydrates. It 
is triangular if the amount of ingested carbohydrate is less than a critical value 
Chcrit. The shape of the curve is trapezoidal if the amount of ingested 
carbohydrate is greater than or equal to Chcrit.  
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                                  Chcrit = [(Tascge + Tdesge) Vmaxge]/2                 (2.3.2.32) 
                                          Tascge = Tdesge = Ch / Vmaxge                      (2.3.2.33) 
       Tmaxge = [Ch – ½ Vmaxge * (Tascge + Tdesge)] /Vmaxge           (2.3.2.34) 
The gastric emptying rate for meals containing carbohydrates greater than 
Chcrit, is  
Gempt  = (Vmaxge/Tascge) t  for t < Tascge,    
 = Vmaxge;   for  Tascge < t ≤ Tascge+Tmaxge,                         
 = Vmaxge-(Vmaxge/Tdesge) (t-Tascge-Tmaxge)    
               for Tascge + Tmaxge ≤ t < Tmaxge + Tascge + Tdesge   and     
 = 0 for other t                                                   (2.3.2.35) 







                                        (2.3.2.36) 
where, 
Tascge, Tdesge = the rising and falling times of the curve (default values = 30  
                         min). Tascge and Tdesge are at their default values when  
                         carbohydrates ingestion is critical and cannot exceed the  
                         critical values. 
Chcrit = the critical value of ingested carbohydrates (10.8 g) 
Tmaxge = the time of plateau for maximum carbohydrate ingestion rate   
Vmaxge = the maximum gastric emptying rate (360 mg/min) 
Gempt  = the gastric emptying rate 
wf = the wave form of the gastric emptying rate  
 
2.3.3 Fabietti Model 
Fabietti et al.’s (2006) model uses 3 equations for insulin dynamics: 
one equation each for intravenous insulin infusion, subcutaneous insulin 
infusion, and the remote insulin compartment. For glucose, two equations are 
used: one for interstitial glucose balance and another for intravenous glucose 
balance. This model embeds intrapatient variability (by including the well-
known circadian insulin sensitivity variation), mixed meal characteristics and 
enables the use of both subcutaneous or intravenous insulin infusion and 
glucose sensor. This model implements the mixed meal model by Arleth et al. 
22 
 
(2000a, 2000b). The mixed meal model includes three terms corresponding to 
classes of carbohydrates in mixed meals (viz. sugar, fast absorption starch, and 
slow absorption starch), and is presented below along with Fabietti et al.’s 
model. 
The insulin sub-model is described as follows: 





++−=                              (2.3.3.1) 
( mLUI /µ= , plasma insulin concentration) 





+−=                                  (2.3.3.2) 
( mLUX /µ= , equivalent insulin concentration in the remote compartment) 





S +−=                                    (2.3.3.3) 
( hUS /µ= , insulin flow from the subcutaneous to the plasma compartment) 
The glucose sub-model is described as follows: 







GG −+++−++−= )(1                  (2.3.3.4) 
( LmmolG /= , blood glucose concentration) 







yg −−= )(                           (2.3.3.5) 
( LmmolY /= , glucose concentration in the interstitial compartment) 
where,                   )
12
sin(1 cccirc P
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msgg AAAE ++=                                      (2.3.3.10) 


















= . (2.3.3.13) 
The hepatic glucose uptake bE is described as follows: 
crb QQE −=                                           (2.3.3.14) 
Glucose release rQ is expressed as: 
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Glucose uptake cQ  is modeled as follows: 








                   (2.3.3.17) 
ggc QEQ += 25.0                                                         (2.3.3.18) 
This model was clinically validated on T1D patients and found to have 
satisfactory performance (Fabietti et al., 2006).  The parameter values are 
provided in Table 2.3. 









Txi 1.81 h 
Ki 0.0101 mL/h 
Tm 2.45 h 
Ti 
1.52 h (regular insulin) 
0.152 h (insulin lispro) 
Tyg 0.194 h 
Tgy 0.194 h 
Kis 0.0481 mL/μU/min 




2.4 Generating a Cohort of Patients for Robustness and Performance 
Studies  
The dynamics of blood glucose can vary from one patient to another 
and indeed in the same patient over time. To reflect these realities, we allow 
the dominant parameters in the mathematical models to vary over certain 
range around their nominal values (e.g. ±40% variation around the nominal 
values). A cohort of patients can be generated by sampling from the space of 
parameter values – each unique combination of these parameters results in a 
virtual patient who is then used to test the robustness and performance of the 
control algorithms. Such an approach was followed in Parker et al. (2000) and 
Ramprasad et al. (2004). 
In Parker et al.’s study (2000), parametric sensitivity analysis was 
performed and 8 parameters namely EIPGU-EГ, EIPGU-DГ, EGHGU-EГ, 
EGHGU-DГ, EGHGP-EГ, EGHGP-DГ, FLC (FHIC), and FPC were identified as 
being most influential in changing the blood glucose and insulin dynamics. 
These are the metabolic parameters described by the threshold functions 
(equation 2.4.1) in metabolic state equations 2.3.2.12, 2.3.2.15, 2.3.2.18, 
2.3.2.26 and 2.3.2.29. 
ГE = EГE {AГE + BГE tanh[CГE (xi + DГE)]}                                    (2.4.1) 
Subscript ‘i’ in equation (2.4.1) represents the state vector element 
involved in metabolic effect and subscript ‘E’ represents the specific effect 
within the model such as the effect of glucose on hepatic glucose production 
(EGHGP), the effect of glucose on hepatic glucose uptake (EGHGU), the 
effect of insulin on peripheral glucose uptake (EIPGU), or the effect of hepatic 
insulin clearance (FLC). The receptor and post-receptor terms (DГE and EГE 
respectively) reflect the inter- and intra-patient variability. These parameters 
are perturbed from their nominal values by ± 40% (± 40% is assumed here due 
to the lack of real physiological data) except for FLC that is limited to ± 20% to 
guarantee non-negative glucose concentrations (Parker et al., 2000). However, 
these combinations of parameters do capture the broad range of physiology 
found in potential patients.  
The nominal values of these eight parameters are presented in Table 
2.2. In Parker et al. (2000) , sets of any three parameters were chosen from 
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these 8 parameters resulting in 56 combinations and each parameter set was 
varied over five levels (max, 0.5*max, no change (nominal value), min, 
0.5*min) resulting in 125 possible variations and a total of 7000 variations 
(including duplicates). However, in Ramprasad et al. (2004), the sets of any 
three parameters are chosen from these 8 parameters, and the chosen 
parameter set was varied over three levels (max, no change (nominal value), 
min) resulting in 15123* 33
8 =C  combinations. Patients with identical values 
for all eight parameters were removed and a set of 577 unique patients was 
generated. These 577 unique virtual patients will be used as test cases in this 
study. 
In the Bergman model, n, p1, p2 and p3 are patient dependent 
parameters. Here, p1, p2 and p3 are chosen as the dominant parameters and are 
perturbed by ±50% from their nominal values. The parameters in the chosen 
parameter set ( 1p , 2p  and 3p ) are varied in three permutations (max, no 
change (nominal value), min) and the combination of these three parameters 
resulted in )27(33 =  virtual patients. These 27 virtual patients are used for 
testing the different control strategies employed in this study. The parameter n 
describes the body mass of average weight person, and is assumed not to vary 
for purposes of this investigation.  
In Fabietti model, iK , xiT , mT  and isK  are chosen for the parametric 
variation study according to Fabietti et al (2006). The range of parameter 
variation is assumed to be ±40% in preliminary studies and ±50% or ±70% in 
later studies as a wider range of patient population is desired.  A similar 
procedure as in Bergman model case is used to produce 81 virtual patients 
which are used for validation of the control algorithms considered in this 
study. 
 
2.5 Automatic Control of Glycemic Regulation in Diabetes  
 Conventionally, an open loop approach such as continuous 
subcutaneous insulin infusion therapy is employed to manage T1D patients. 
Such methods require that finger pricks be performed anywhere between 3 to 
7 times each day to get BG measurements followed by as many times of 
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insulin injection of insulin. This can place a heavy burden on patients. 
Automatic control strategies are now being studied for T1D glycemic 
regulation and are found to be promising. Many control algorithms for 
regulation of blood glucose concentration using insulin infusion are developed 
in the literature. These range from simple Proportional- Integral-Derivative 
(PID) controllers to nonlinear controllers to advanced model based control 
algorithms that are able to handle practical constraints in a formal manner (e.g. 
Model Predictive Control (MPC)). Some of the more significant works in this 
area are reviewed here.  
  
2.5.1 Insulin Administration Routes Used by Control Algorithms 
Automatic controllers have been proposed for administering insulin via 
the intravenous or subcutaneous route. Intravenous insulin delivery comes 
with inherently significant advantages such as: (1) reduction of the time delay 
that is experienced with subcutaneous insulin delivery (2) faster response to 
hyper- and hypo-glycemia, and (3) high potential for improving closed-loop 
performance (mainly as a result of the first two points mentioned). For these 
reasons, some studies have preferred to consider intravenous insulin 
administration. However, this type of administration is associated with 
catheter in-dwelling, dislodging from vein and occluding. To overcome these 
disadvantages, subcutaneous insulin administration is utilized in current 
technology and insulin pumps capable of subcutaneous administration are 
available in the market. Subcutaneous insulin infusion using these insulin 
pumps is associated with irritation and infections at the site of administration.  
 
2.5.2 Control Strategies used for Glycemic Regulation in Diabetes  
A comprehensive review of control algorithms that used intravenous 
route is available in Parker et al. (2001). Their work covers research reported 
until 1999. Here, we summarize the work on T1D control algorithms with 
particular emphasis on works reported from 1999 to 2009. A control algorithm 
that utilized intravenous insulin administration was first employed in the 
glucose controlled insulin infusion system (GCIIS) by Pfeiffer et al. (1974). 
The Biostator algorithm of Clemens (1979) used the feedback controller with a 
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dual infusion system (insulin and dextrose) to keep blood glucose 
concentration at user-specified values. A nonlinear proportional plus 
derivative controller with a five-point moving average of glucose 
measurements was used to reduce the effect of noisy glucose measurement. 
This algorithm may be appropriate for bedside implementation but the dual-
reservoir system makes it somewhat difficult to use in mobile patients or for 
use on a regular basis. Individualization of the algorithm is also required to 
make it effective on patients. 
Albisser et al. (1974) also used dual-channel system (insulin and 
dextrose infusion) in which insulin infusion is controlled by a projected value 
of blood glucose concentration that was computed using current measurement 
value of BG along with an exponential difference factor obtained from four-
minute average rate of change of BG. Individualization of patient dependent 
parameters was also required for this algorithm. This algorithm was modified 
later by many researchers: Botz (1976) lessened the postprandial 
hypoglycemia by modification on the rate dependent component to be similar 
to absolute rate of BG and eliminated the dextrose infusion; Marliss et al. 
(1977) also lessened the postprandial hypoglycemia by modification on the 
rate dependent component but retained dextrose infusion for safety reason 
although it was rarely used. Kraegen et al. (1977) used weighted average rate 
of BG over previous four minutes to reduce the controller response to the 
noise. Fischer et al. (1978) developed a linear control algorithm based on the 
experimental data. Broekhuyse et al. (1981) compared the performance of 
these algorithms and concluded that significant further development in 
controller design was needed for BG regulation in diabetes patients. Bellomo 
et al. (1982) extended the static Biostator control algorithm by updating the 
patient model parameters using the experimental data by minimizing an 
integral of squared performance index in the glycaemia excess and insulin 
infusion rate but the results still showed significant hyperglycemic peaks. 
Furler et al. (1985) developed a control algorithm using a saturation function 
in which the insulin delivery rate was calculated as a function of current 
glucose measurement on the extended version of ‘minimal model’ but meal 
disturbance rejection was not considered.  
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Fischer et al. (1987) developed a control algorithm in which controller 
performance was markedly improved by customization to the specific patient; 
however, a one minute sampling interval was used for glucose measurements. 
Such fast sampling is not yet possible on a routine basis. Sorensen (1985) 
designed an internal model controller (IMC) based on a First Order Plus Time 
Delay (FOPTD) approximation of the 19th-order nonlinear model and obtained 
adequate BG regulation performance. However, significant performance 
degradation was experienced if patient parameters were uncertain. Parrish and 
Ridgely (1997) used state-dependent Riccati equations and designed a 
controller based on partial linearization but the tracking performance showed 
steady-state offset. Kienitz and Yoneyama (1993) used H∞ control for BG 
regulation and the controller performance was found to be satisfactory for 
patients whose parameters were within the design set. However, over a wider 
range of parameter values, retuning of the controller parameters was required. 
Optimal control theory has also been applied for blood glucose control 
in Type 1 Diabetic (T1D) patients. Swan (1982) used optimal control theory 
on the linear diabetic patient model in which the insulin delivery rate was a 
function of both the current insulin and glucose concentrations. The author 
focused on a diabetic patient with initial hyperglycemic condition; however, 
meal disturbance attenuation was not treated. Fischer and Teo (1989) tested 
various insulin infusion protocols with the objective to minimize the sum of 
squares of glucose tracking error. They considered a patient with initial 
hyperglycemia and also the regulation of blood glucose during meal 
consumption. Impulse control was found to be efficient if a good estimate of 
the rate of glucose entering into blood from intestinal absorption of ingested 
meal was available.  Lim and Teo (1991) used impulse control for the same 
situations but included parameter uncertainty and reported their strategy to be 
robust and numerically stable.  
Optimal control theory was applied on the ‘minimal model’ by 
Ollerton (1989) using the integral squared error (ISE) objective function to 
minimize the deviation of measured glucose value from the desired glucose 
value using 10 min and 180 min sampling intervals. However, their insulin 
profiles were physiologically unrealistic as they displayed high amplitude 
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sustained oscillations about the basal state. Fischer (1991) used optimal 
control theory with an ISE-type objective function on ‘minimal model’. A 
secondary objective of minimizing the amount of insulin infusion for a patient 
with an initial hyperglycemic state was also considered. However, their 
controller was not robust to parametric uncertainty. It was also found that if 
the 180 min sampling interval was adopted, there was a very high chance and 
penalty of missing the inter-sample disturbance(s). 
Parker et al. (1999) and Parker (1999) implemented MPC with and 
without state estimation for blood glucose control on the modified version of 
the Sorensen (1985) model. Constraints were set for insulin delivery rate and 
for the rate of change of insulin. The controller performance was found to be 
good for an unmeasured 50g meal disturbance.  The nonlinear quadratic 
dynamic matrix control with state estimation (Gattu and Zafiriou, 1992) was 
also studied but the nonlinear controller did not show any significant 
improvement over the linear MPC. Parker et al. (2000) used the H∞ framework 
on the 19-state nonlinear ODE model with the model uncertainty and 
evaluated the disturbance rejection criteria on 577 virtual patients (generated 
with parametric perturbations) and found that the performance of the H∞ 
controller was comparable to that of the computationally-intensive MPC. 
Camelia and Doyle (2001) used the IMC framework on the minimal 
model and on the Automated Insulin Dosage Advisor (AIDA) model of 
Lehmann and Deutsch (1992) but the inherent uncertainties in the model were 
not addressed. Lam et al. (2002) employed heavy derivative PD controller on 
Bergman’s minimal model and tested the performance of the proposed 
controller on the simulated model (with multiple meals) with the available 
sensor sampling time. They tested the effect of three successive sensor failures 
and sensor lag. Promising results were obtained but oscillations and instability 
were observed in the presence of measurement noise.  
Ruiz-Velazquez et al. (2004) used H∞ controller for set point tracking 
of blood glucose in the presence of meal disturbance. Their work used 
Sorensen (1985) T1D model with Lehmann and Deutsch (1992) meal model. 
With their strategy, hyperglycemic condition was found to persist for a 
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significant amount of time leading to questions on the appropriateness of this 
controller.  
Hovorka et al. (2004) employed an adaptive nonlinear model 
predictive controller (adaptive NMPC) to keep blood glucose in 
normoglycemic region. This controller used the model developed by Hovorka 
et al. (2002). Bayesian parameter estimation was used for re-estimating 
parameters at each control step with the objective of minimizing the weighted 
sum of squares of residuals (actual BG minus estimated BG) and a penalty due 
to the deviation from prior distribution of standardized model parameters in 
the learning window. The controller performance was validated clinically on a 
cohort of T1D patients who were fasting overnight. Subcutaneous insulin 
infusion was provided using an insulin pump with the input constraint on 
insulin infusion rate. Hovorka et al. used an intravenous glucose sampling 
interval of 15 min.  The results were promising for blood glucose control 
during overnight fast but the performance of the controller on meal 
disturbance rejection criterion was not considered.  
Ramprasad et al. (2004) employed PID controller for blood glucose 
control in T1D patients with different tuning methods and tested the 
robustness of these controllers for meal disturbance rejection scenarios (both 
single- and multiple-meal disturbance(s)). They obtained best results with 
Shen’s (2002) tuning method, and demonstrated that hypoglycemia 
(<60mg/dL) could be avoided in 95% of a cohort of 577 virtual patients 
constituted from Parker et al.’s (1999) model. Frequent sampling was assumed 
for blood glucose measurement according to current glucose sensor 
technology (available at every 4 min).  
Schlotthauer et al. (2005) used NMPC for the control of blood glucose 
in T1D patients.  In their work, Multi-Layer Perceptron networks (MLP) were 
used for prediction of BG values. They used the Cobelli’s (1983, 1998a, 
1998b) model to represent the T1D patient, introduced linear first order 
dynamics for subcutaneous BG measurement and employed subcutaneous 
insulin injections for blood glucose control. Their results were quite promising 
in the context of meal disturbance rejection but they did not consider the 
presence of measurement noise or changing patient dynamics. Therefore, 
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robustness and stability issues were left unresolved. A good review on the use 
of adaptive control for blood glucose control in T1D patients can be found in 
Hovorka (2005). 
Canonico et al. (2006) used a novel PID-type controller named 
Proportional-Derivative-2nd derivative (PDD2) controller and tested it on 
virtual patients constituted from the T1D patient model of Fabietti et al. 
(2006). Better results were obtained compared with the standard insulin 
therapy of continuous subcutaneous insulin infusion (CSII) protocol. 
However, the authors did not mention the frequency of measurement of blood 
glucose concentration. 
  An overview of mathematical models and software tools employed in 
the study of glucose-insulin regulatory system can be found in Makroglou et 
al. (2006).   
Ibbini (2006) proposed a PI-fuzzy logic controller (PI-FLC) for blood 
glucose control in T1D patients. While there is no need for precise 
mathematical models with this strategy, it appears to require considerable 
human expertise to make it work well. The simulation results showed smaller 
overshoot, shorter settling time, smaller area under the curve above the set 
point and acceptable BG limits in the presence of meal disturbances and in the 
presence of uncertain parameter values when compared to other controllers 
such as LQR (Optimal Linear Quadratic Regulators), PI, PID and FLC with 
frequent BG sampling. However, Ibbini (2006) did not consider the presence 
of measurement noise.  
An advanced model based controller based on parametric 
programming was investigated by Dua et al. (2004). In their strategy, optimal 
insulin infusion was calculated off-line as an explicit function of the current 
blood glucose concentration of the patient. This has the advantage of using 
simple function evaluations for calculating insulin infusion in on-line 
applications. The Bergman ‘minimal model’ was used as a virtual patient with 
the model discretized with a sampling time of 5 minutes (to be compatible 
with current glucose sensor technology). The model predictive controller with 
the objective of minimizing a quadratic function of state variables and insulin 
infusion rate with constraints on glucose concentration (60~120mg/dL) and on 
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insulin infusion rate (0~100mU/min) was solved using the multi-parametric 
quadratic programming (mp-QP). This work was later extended in Dua and 
Pistikopoulos (2007) where patient parametric uncertainty was taken into 
account. Two meal disturbance models (Fischer (1991), and Lehmann and 
Deutsch (1992)) were used. An asymmetric function that penalizes 
hypoglycemia more than hyperglycemia was also considered. Hypoglycemia 
was successfully avoided but high glucose peak values resulted with the meal 
disturbance. A tutorial and overview on the model-based constrained control 
of T1D is provided in Doyle et al. (2007).  
Marchetti et al. (2008a) applied PID switching control in which bolus 
injection is applied for meal disturbances (prior to meals) and a switch to PID 
controller between meals. Time varying setpoint and measurement noise were 
considered in their work. A derivative filter was used to deal with sensor 
noise. Marchetti et al. (2008a) used the Hovorka model (2004) along with the 
update proposed by Wilinska et al. (2005). They also leveraged the switching 
strategy to tackle the tradeoff between hypoglycemia and the peak value of 
postprandial BG response. The robustness of their strategy was demonstrated 
by considering daily insulin sensitivity variation that may arise from 
physiological changes. Marchetti et al. (2008b) studied a kind of feedforward-
feedback control using PID for T1D patients on the same model. They 
proposed the use of pre-prandial snack or insulin bolus or the reduction of BG 
setpoint before meal to reduce the BG peak of postprandial responses. The 
results of feedforward-feedback control strategy (5 min BG sampling) with 
PID controller were found to be promising even in the face of changes in 
insulin sensitivity. A model reference approach was also evaluated with the 
feedback controller – this pointed out the need for a reasonably accurate 
reference model. The results are promising and deal with many practical 
considerations that are relevant for diabetic patient care. Other scenarios such 
as exercise effect and robustness while considering a broad range of patients 
have not been addressed.   
Eren-Oruklu et al. (2009) demonstrated an adaptive control strategy 
using general predictive controller (GPC) and linear quadratic controller 
(LQC) for regulation of blood glucose levels in patients with T1D patients. 
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System identification methods were used to obtain the patient model in Auto 
Regressive Moving Average (ARMA) form which was then used to predict 
glucose level 30 min (6 steps) ahead. In closed loop condition, the Auto 
Regressive Integrated Moving Average with eXogenous input (ARIMAX) 
model is used. The model parameters are updated continuously using recursive 
least squares (RLS) method to handle the intra- and inter-patient variability. 
Both subcutaneous BG measurement and subcutaneous insulin infusion are 
employed along with a delay compensator and one step ahead BG prediction.  
The algorithm is quite successful and is applicable to single rate data system.  
All the algorithms described above have only dealt with single rate 
system, and this can be a limitation in BG control for T1D patients.  
 
2.6 Intensive Insulin Infusion Therapy and Diabetes Control  
Critically ill patients or patients in ICU experience stress induced 
hyperglycemia even if they do not have any past history of diabetes. Other 
factors such as presence of hypertension, cortisone and pancreatic disease also 
result in hyperglycemia. From the extensive literature, it is clear that intensive 
insulin therapy (IIT) can reduce morbidity, mortality and duration of patients’ 
stay in ICU. According to Leuven study, an IIT that maintains BG in the 
80~110mg/dL range can reduce ICU mortality by 42%, bloodstream 
infections, the incidence of acute renal failure, the need for prolonged 
ventilatory support and the duration of ICU stay (Goldberg et al., 2004).  
Many IIT protocols have been developed for glycemic control in ICU - 
some protocols have been developed in medical ICU (MICU) and some 
protocols have been proposed for use in surgical ICU (SICU). These protocols 
still need to be optimized so as to be effective on a broad range of patients (i.e. 
tight and safe blood glucose control). Use of the ad-hoc protocols based 
primarily on experience is practiced in many ICUs. Avoiding hypoglycemia is 
the primary intention for patients in ICUs. It would be worthwhile to develop a 
protocol that can: (i) avoid hypoglycemia, (ii) provide tight glycemic control 
for the different conditions of patients with minimal physician intervention, 
and (iii) is easy to use by ICU medical staff involved in patient care. Other 
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control algorithms used in glycemic control for ICU patients include PID 
using sliding scale method (Chee et al., 2003) and MPC (Plank et al., 2006).  
The patient model used for ICU patients includes the pancreatic 
function (Chbat et al., 2005), which is different from almost all other T1D 
patient models. Developing a patient model that takes into account conditions 
such as hypertension, corticosteroid expression, enteral (i.e., nutrition 
administered through a tube via the nose or stomach or the small intestine) or 
parenteral (i.e., nutrition administered via a peripheral or central vein) is still 
an open problem that, when solved, can be highly useful in ICU settings.   
 
2.7 Diagnostic Tests  
 The most common diagnostic test for diabetes is based on fasting 
plasma glucose (FPG) concentration. The FPG of normal subjects is 
110mg/dL (6.1mmol/L) and diabetes is suspected (diagnosed) if FPG is more 
than 126mg/dL (7.0mmol/L). If the FPG value is between 110mg/dL and 
126mg/dL, this condition is defined as pre-diabetes and may need further 
confirmatory tests.  
Alternate indications of diabetes is based on the causal plasma glucose 
(CPG) i.e. BG value at any time of the day. If CPG is more than 200mg/dL, 
further tests such as FPG and measurement of glycated hemoglobin (HbA1c) 
levels are recommended. Sometimes, the oral glucose tolerance test (OGTT) is 
conducted. Herein, if the post-prandial glucose (PPG) measure taken after 2hr. 
following an oral intake of 75g glucose exceeds 200mg/dL (11.1mmol/L), the 
patient is diagnosed as having diabetes. In another test known as the 
intravenous glucose tolerance test (IVGTT), glucose with/without insulin is 
infused intravenously and BG is measured frequently for up to 3 hours. This 
test is definitely more invasive and involves the deployment of more human 
and material resources and therefore seldom used. However, with IVGTT, the 
dynamics of blood glucose and insulin interaction can be understood distinctly 
and so is employed for research purposes. A modified version of this test is 
developed and applied in this study as a classification test; details of the test 
will be described in chapter 4. 
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2.8 Finding a Model from Diabetic Patient Data 
 In the above sections, the patient’s model is pre-specified and an 
appropriate control algorithm that employs nominal patient parameters is 
applied. Such an approach relies significantly on the benevolent nature of 
feedback mechanism in its tolerance to model-patient mismatch. An alternate 
approach that intends to make the medical care personalized to the patient is 
possible. Here, a suitable mathematical model is identified based on data 
collected from the patient prior to and during the period of treatment. A 
suitable controller is designed based on the deduced model with sufficient 
safeguards to take care for imprecision in parameter estimates. System 
Identification (SID) tools are quite handy in obtaining an adequate 
mathematical model from the input and output data collected from the patient 
even when the biochemical, biophysical characteristic of the disease is 
unknown; this type of modeling is called black-box modeling. As mentioned 
earlier, the study by Eren-Oruklu et al. (2009) used such an approach. The data 
sets used for system identification is generally assumed to have regular and 
similar sampling intervals for all input and output variables. Such regular and 
single-rate sampling is sometimes not possible particularly in medical settings. 
In many practical situations, data are sampled at different sampling rates and 
results in the so-called multirate system. Making models from such data is 
more difficult compared to making models from single-rate data, and calls for 
special multirate system identification methods. The nature of diabetic patient 
data is described next. 
 
2.8.1 Multirate Nature of Diabetic Patient Data 
Different from single rate systems in which inputs and outputs are 
measured at one identical sampling interval, multirate systems are sampled-
data systems with non-identical sampling intervals. Multirate systems are very 
common in chemical process industries where different variables are sampled 
at different rates for some practical reasons.  
In the chemical industries, measurements from the units such as 
distillation columns and reactors are available at different sampling rates. 
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Variables such as temperature, pressure, flowrate etc. can be measured 
frequently while composition measurements, molecular weight distribution, 
melt flow index etc. can be obtained once every several minutes or even 
several hours due to hardware limitations. These features naturally lead to a 
multirate system. 
 Data obtained from diabetic patients tend to be multirate in nature: BG 
measurement is usually obtained infrequently and may be available on an 
irregular basis; however, the insulin infusion rate is measured more frequently. 
Such multirate data needs multirate system identification tools to identify the 
relevant models that may be beneficially used to achieve tight BG control.  
 
2.8.2 Multirate System Identification  
Most of the successful system identification methods in both 
polynomial (transfer function) domain and state space domain are applicable 
only to single-rate input/output data. Very few algorithms have been 
developed for multirate identification (MRID) which can process multirate 
input/output data. Conventionally, engineers interpolate the inter-sample 
input/output from the slowly sampled measurements and then estimate the 
model (fast-rate model) based on both the measured and interpolated data set. 
The model obtained from traditional interpolation techniques cannot capture 
the actual model dynamics very well when the ratio of sampling intervals 
(slow measurement interval/fast measurement interval) becomes large. This is 
because the interpolation does not take the actual dynamics of the process 
(between the intervals of each successive slowly sampled instance) into 
account. It is clear that a more reasonable systematic approach which takes 
into account the multirate nature of the process is required. This is offered by 
multirate system identification.  
Lifting technique plays an important role in multirate system 
identification; it converts a multirate system into a single rate system to which 
most of the system identification techniques can be applied successfully. 
Verhaegen and Yu (1995) presented a technique to estimate the lifted model of 
a multirate system in state-space (SS) form. They represented the multirate 
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system as a periodic system, and they estimated the lifted model using the 
multivariable output-error state space method. Their method cannot handle the 
crucial causality constraint (i.e., the state space model should be observable 
and controllable) in the identification of lifted models if the system time delay 
is greater than p  (Li et al., 2001) for Single Input/Single Output (SISO) 
multirate system with input (U ) and output (Y ) which are sampled with 
sampling interval ( pm× ) and ( pn× ) respectively ( m n , :n m γ= and p = 
base time period, both m and n are coprime). Li (2001) made modification 
(shifting the data for the system with time delay greater than p ) of their earlier 
work to effectively overcome the causality constraint when both m and n are 
coprime. With this modification, most of the existing system identification 
algorithms can be applied for identification of the lifted (slow-rate) system.  
Identification of the slow rate model is possibly best accomplished 
using state space methods which can handle multivariable processes. Li et al. 
(2001) also proposed some approaches to extract the fast rate model with 
sampling interval 𝑚𝑝 (where 𝑚 >1) from the slow rate model. Wang (2004) 
improved Li et al.’s work in a manner such that the fast rate model could be 
readily extracted at the fastest sample time (base time period, p ) with (1) 
matrix roots approach based on the condition that slow-rate state matrix A  in 
SS model is diagonalizable and (2) frequency-domain approach in which 
applying the polyphase decomposition developed by Khargonekar et al. (1985) 
to the lifted slow rate system.  Note that all of these works are valid in the 
context of linear systems only. The application of multirate system 
identification onto nonlinear systems can be seen in Ooyama et al. (1999).    
Gopaluni et al. (2003) proposed a multirate identification algorithm in 
which they used an iterative identification algorithm. In this work, they first 
identified a Finite Impulse Response (FIR) model from multirate data. Based 
on this model, the missing data points in the slow sampled measurement are 
estimated using the expectation maximization approach. Then, they estimated 
a new model iteratively using the estimated missing data points and original 
data set until the models converge. Their method is also applicable to 
irregularly sampled data system. May Su Tun et al. (2006) developed data 
selection and regression (DSAR) method for the identification of multirate 
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system. The advantage of DSAR is that it is able to handle the large ratio of 
sampling intervals as well as irregularly sampled data. 
 
2.9 Conclusions  
 In this chapter, the literature review and basic elements regarding 
regulation of BG in T1D using artificial pancreas are discussed. The review of 
Type 1 diabetic patient models and associated meal models is presented in 
section 2.1. The uncertainty issues regarding patient models, the detailed 
description of chosen T1D model and associated meal model for this study and 
the generating cohort of patients to test robustness and performance of control 
algorithms that will be developed in later chapters are described in section 2.2, 
2.3 and 2.4 respectively. The automatic control of BG in T1D patients and 
review of control algorithms is presented in section 2.5. This pointed out the 
need for robust control algorithms that can handle a broad range of patient 
variations and the need for a more realistic approach to obtain the personalized 
model and control algorithm. To achieve these goals are the scope of the 
present study. The intensive insulin infusion therapy applied in ICU is 
described briefly in section 2.6 and it appears that such an approach may be 
extended for BG control in T1D patients. The descriptions of patient 
diagnostic tests and a modified test that will be used for patient classification 
in later chapters to develop a more personalized care are expounded in section 
2.7. Finally, estimating patient models from multirate data (that is more 
realistic) using multirate system identification is introduced in section 2.8 to 









 It is well understood that the maintenance of plasma glucose 
concentration in normoglycemic range is crucial to the individuals’ well-being 
in all types of diabetics. This is mainly achieved by administering the right 
dose of insulin around the clock in an effective manner. To achieve this, 
closed loop feedback control has been considered by many researchers. Chee 
and Fernando (2007) provide an excellent introduction to the modeling, 
control and miniaturization aspects of the blood glucose control (artificial 
pancreas) problem. Control algorithms of varying sophistication from PID 
(proportional, integral and derivative) control to Model Predictive Control 
(MPC) have been employed for BG control in T1D patients (Bequette, 2005). 
Different from these automatic feedback controllers, rule-based insulin 
infusion protocols (IIP) have been developed and employed in hospitals for 
glycemic control in ICU (Intensive Care Unit) patients. Patients in surgical 
and/or medical ICUs frequently experience stress induced hyperglycemia and 
impaired glucose metabolism even though they may or may not have a prior 
history of diabetes. Poor glycemic control in ICU patients has been linked to 
increased morbidity and mortality rates for patients who have been treated for 
three or more days in the medical ICU (Van den Berghe et al., 2006).  The 
seminal study by Van den Berghe et al. (2001) showed the benefits of tight 
glycemic control in patients at a surgical ICU. Later trials by other medical 
teams in other ICUs indicated that the Van den Berghe’s protocol (and other 
similar ones) resulted in hypoglycemic episodes and needed reconsideration. 
Since then, several IIPs that have been fine-tuned to prevent hypoglycemia 




3.2 Motivation and Objectives 
A thorough study on how a typical IIP (Yale IIP, YIIP is used here as 
an example; its details are described in Appendix A. 1) fares in treating T1D 
patients would be instructive. Even though the IIPs are originally intended for 
treating ICU patients, would it be applicable for routine insulin-infusion based 
treatment of T1D patients (with normal meal of three meal disturbances:- 10g, 
50g & 50g for breakfast, lunch & dinner respectively). This is the main 
objective of the present study. If the IIP (with some modifications) works as 
well as a traditional control algorithm, it can be easily used by T1D patients 
(because an IIP is based on a table lookup and simple calculations) to adjust 
their periodic insulin intake or be easily programmed for use by feedback 
control schemes.  
Note that the IIPs are very amenable to straightforward implementation 
into integrated sensing and programmed implantable insulin delivery devices. 
The main difference between a T1D patient and a typical ICU patient is the 
absence of pancreatic insulin secretion in the former while the pancreatic 
function is existent but possibly inadequate in the latter (Chbat et al., 2005). If 
hypoglycemic episodes are observed in the predefined broad range of patients, 
the standard YIIP will be modified so as to avoid hypoglycemia.  
 
3.3 Yale Insulin Infusion Protocol 
 Stress during critical illness induces glucose counter regulatory 
hormones, increases insulin resistance and relative insulin deficiency resulting 
in hyperglycemia. Furthermore, several common interventions such as 
corticosteroids, vasopressors, enteral or parenteral nutrition also result in 
higher BG levels. Van den Berghe et al. (2003) reported that the use of 
intensive IIP in patients of a surgical ICU (SICU) resulted in normalization of 
BG level and reduced mortality rates. 
Yale IIP (YIIP) by Goldberg et al. (2004) is the outcome of a similar 
study on ICU patients but implemented in a Medical ICU (MICU). It was 
designed to implement effective IIP for strict glycemic control in MICU of 
Yale New Haven Hospital, USA. The protocol was intended for easy use by 
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nursing staff without the need for frequent physician input. YIIP was aimed to 
keep the patients’ BG level within a conservative BG target of 100~139mg/dL. 
This algorithm is based on three main data elements used by experienced 
clinicians to adjust insulin infusion: (1) the current BG value, (2) the previous 
BG value, and (3) the current insulin infusion rate. Thus, the IIP is based on 
the rate of BG changes rather than on absolute BG values. In reported IIP 
works, the initial insulin infusion (including bolus) is based on the current BG 
level of the patient. Admittance to IIP starts when the patient’s BG level 
exceeds 200 mg/dL. The same amount of insulin the initial insulin infusion 
amount is injected as bolus at the initialization of this IIP. Initial insulin 
infusion lasts for one hour before continuous BG monitoring is started. The 
rate of insulin infusion is updated whenever BG value is monitored - the 
frequency of BG monitoring may also change depending on the value of the 
last noted BG value and the most recent BG trend. The monitoring of patients’ 
BG level is done on hourly basis in general but a different frequency of 
monitoring (30 minutes or 15 minutes) can be used depending on the severity 
of patient’s hypoglycemic condition: the BG monitoring is required at every 
15 min when the patient’s BG value is under 75mg/dL, it changes to at every 
one hour when the patient’s BG is within target range (100~139mg/dL), it 
changes to at every 2 hours when three consecutive BG values become stable 
(in target range), etc.; and more details of YIIP can be seen in Appendix A. 1. 
The primary importance of avoiding hypoglycemia (<60mg/dL) is handled by 
using of intravenous dextrose, as per protocol when the patient BG value is 
less than 75mg/dL.  
In YIIP, the missing data values are estimated by averaging known BG 
levels from the hours before and after missing values. The YIIP was 
successfully implemented in a MICU in which nearly 40% of MICU patients 
are admitted for primary respiratory failure. This IIP was subsequently 
validated on 52 patients from the same MICU. In their (Goldberg et al., 2004) 
study of 5,808 subsequent hourly blood glucose values, only 20 (0.3%) BG 
values from 12 patients fell below 60mg/dL and only three BG values were 
less than 40mg/dL. Such hypoglycemic episodes were rapidly corrected by 
intravenous dextrose infusion. Compared to a group of 47 patients who 
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received conventional insulin therapy (intravenous or subcutaneous insulin), 
the patients who received YIIP had better glycemic control. Similar protocols 
have been developed and used in other hospitals/clinics (see Chant et al, 
2005).  
Full details of the YIIP (taken from Goldberg et al., 2004) are provided 
in Appendix A. 1. Note the precautions, the insulin infusion initialization 
process, rules for adjusting infusion rates, adjustments to BG monitoring 
frequency etc. 
 As indicated earlier, one of the goals of the present study is to check 
how IIP protocols such as the YIIP work on T1D patients. Towards this end, 
in silico patients generated from popular T1D patient models will be utilized 
for this investigation. The generation of the patient cohort and the results of 
application of YIIP to this cohort are described next. 
 
3.4 Cohort of Patients 
      There is natural variability in the physiological behavior of diabetic 
patients, and this is reflected as variability in parameters of the diabetes patient 
models. In fact, even in a single patient, the response can vary over time and 
this can be modeled as gradual or abrupt variations in model parameters over 
time. Here, it is assumed that the dominant parameters deviate by a certain 
percent (± 20% or ± 40%) about their nominal values. The combination of 
these parameter variations results in a cohort of potential patients for each 
model. The in silico patients resulting from this procedure are used to test the 
control algorithms for robustness and performance.  
In the model described in Parker et al. (2000), 8 parameters namely 
EIPGU-EГ, EIPGU-DГ, EGHGU-EГ, EGHGU-DГ, EGHGP-EГ, EGHGP-DГ, 
FLC (FHIC), and FPC are chosen as varying from one patient to another. These 
8 parameters are perturbed from their nominal values by ±40% (except for 
FLC that is limited to ±20% to guarantee non-negative glucose concentration 
as mentioned in Parker et al., 2000). From these 8 parameters, sets of any three 
parameters are chosen and the chosen parameter set is varied in three levels 
(max, no change or nominal value, min) resulting in 15123* 33
8 =C  
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combinations. Patients with identical values for all eight parameters were 
removed and a set of 577 unique patients was generated as in Ramprasad et al. 
(2004). These 577 unique virtual patients are used as test cases in this study. 
In Fabietti model, four parameters (namely, iK , xiT , mT  and isK ) are 
chosen to generate the virtual patients. These four parameters are perturbed by 
±40% from their nominal values (see these values in Table 2.3). These 
parameter variations are within the experimental parameter values of Fabietti 
et al. (2006). The combination of these parameters results in a cohort of 
potential patients. The chosen parameter set is varied in three levels (max, no 
change or nominal value, min) for each parameter, and the combination of 
these four parameters result in 43 ( 81)=  simulated patients. These simulated 
patients are also used to test the performance of the control algorithm.  
 
3.5 Details of the Study 
The effectiveness of YIIP is evaluated in silico i.e. on the T1D patient 
cohorts generated. The YIIP algorithm is coded and evaluated on the cohort of 
patients described in Section 3.4. The computations are done in MATLAB 
platform using SIMULINK. The effectiveness of the IIP algorithm in terms of 
disturbance rejection and its robustness are tested on cohorts of virtual T1D 
patients for a “normal” day with three carbohydrate meal disturbances of 
breakfast (10 g), lunch (50 g), and dinner (50 g) at the meal times of 7 am, 12 
noon, and 6 pm respectively. Both glucose sensing and insulin infusion are 
administered through intravenous route using portal vein for the advantages of 
using intravenous route, described in Section 2.5.1. In this study, measurement 
noise and input constraints (except that insulin infused cannot be negative) are 
not considered as it is desired to understand the ideal performance of the 
proposed strategy. 
 
3.5.1 Method I: YIIP 
The YIIP was developed for MICU patients, and it is yet to be 
validated on a broad range of T1D patients. The effectiveness of YIIP on the 
cohort of T1D patients described in Section 3.4 is studied by subjecting the 
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“patients” to three meal disturbances for 3 consecutive days. The details of 
YIIP have been provided in Appendix A. 1; intravenous route is used for 
insulin infusion and dextrose infusion (the duration for this infusion is 
simulated as 1 hr generally in this study) is given should there be a 
hypoglycemic episode. As mentioned, the initial insulin infusion amount is 
calculated based on the patient BG value, and same dose of bolus insulin is 
administered at the very start of algorithm. 
 
3.5.2 Method II: Modified YIIP (MODYIIP) 
The target of YIIP is conservative (100~139mg/dL) because it is 
designed to be safe to avoid hypoglycemia as strict blood glucose control 
(maintaining BG within 81~108mg/dL) has adverse effect on mortality rate 
(Studer et al., 2010). However, the results from the study of YIIP on chosen 
diabetic patient models show the amount of initial insulin infusion should be 
suitably adjusted. Extra glucose infusion is used in YIIP in case of 
hypoglycemia events but it is burdensome for T1D patients to carry the 
glucose reservoir, and it would be advantageous if we can modify insulin 
infusion amount.  
To improve its applicability in out-of-ICU settings and especially to 
avoid hypoglycemia in patients without the use of extra dextrose/glucose 
reservoir, the initial insulin infusion amount of YIIP will be modified suitably 
in this work leading to the development of a new modified YIIP algorithm 
(MODYIIP). The initial insulin infusion for each of the 577 patients (Parker 
model type) is modified according to their BG response to the original initial 
amount of insulin (Parker model type patients are chosen here as these type of 
patients are more sensitive to insulin). If any particular patient exhibits 
hypoglycemia (BG < 70mg/dL) with original insulin infusion amount, the 
amount of initial insulin infusion is reduced to 75% of its original value. If it 
still results in hypoglycemia, the insulin infusion is reduced to 50% of original 
amount. The procedure is repeated (i.e. to 25% and 0%) until the BG value is 
in the range of normoglycemic region. A similar procedure is applied by 
increasing the infusion amount (125%, 150%, 175% and 200%) if any patient 
shows hyperglycemia (BG > 110mg/dL 3 hours after meals). During the 
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validation of the modified YIIP on other patient models, insulin infusion is 
assumed to be via the intravenous route. 
Using the “fminsearch” tool (expect in Hovorka model patient where it 
is infused through the subcutaneous route) available in MATLAB, the idea 
was tested on the 577 Parker model type patients with initial BG value of 
around 150mg/dL. The objective was to determine the optimal insulin infusion 
amount that avoids hyperglycemia in all patients. It was determined that no 
hypoglycemic episode occurs when the initial infusion limit is set at 50% of 
original YIIP initial insulin infusion. With this reduced initial insulin amount, 
the lowest BG value reached was 75mg/dL and the highest BG value attained 
was 235.94mg/dL. The hyperglycemic episodes are compromised here to 
avoid dangerous hypoglycemia using 50% of its original values and to make 
the modified YIIP (MODYIIP) safe for T1D patients. Therefore, the 
MODYIIP is one in which only 50% of initial insulin infusion as 
recommended by standard YIIP is chosen. Note that, in MODYIIP, there is no 
need for glucose infusion to avoid hypoglycemia.  
 
3.6 Results and Discussion: YIIP on T1D Patients 
The application of the YIIP protocol is aimed to test its effectiveness 
and applicability on a broad range of T1D patients constituted from two 
diabetic patient models (Parker and Fabietti Model) with three meal 
disturbances and to study how to improve its applicability on T1D patients. 
Three carbohydrate meal disturbances - breakfast (10 g), lunch (50 g), and 
dinner (50 g) at the meal times of 7 am, 12 noon, and 6 pm respectively – are 
considered in this study. The performance of meal disturbance rejection of 
YIIP on 577 constituted patients using Parker model with three meal 
disturbances per day over a three day period is presented in Figure 3.1 (with 
initial blood glucose value of 81. 08mg/dL) and Figure 3.2 (starting from 
initial hyperglycemic state of BG~150mg/dL). The Lehmann and Deutsch 
(1992) meal model is used in these simulations.  
According to the results on Parker model with hourly BG monitoring 
(Figure 3.1), 423 patients and 547 patients out of 577 patients record a BG 
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value in excess of 139mg/dL for normal initial condition and initial 
hyperglycemic condition respectively. The highest BG peak values for these 
two cases are 207.99mg/dL and 211.42mg/dL respectively. For the normal 
initial condition, 15 patients (2.6%) experience hypoglycemia (< 60mg/dL) 
with lowest BG value being 52.61mg/dL. When the initial condition is 
hyperglycemic, 12 patients (2.08%) enter into hypoglycemic region 
(<60mg/dL) with lowest the BG value being 53.99mg/dL. Note that, in these 
subsets of patients, severe hypoglycemia has been avoided by the use of 
dextrose infusion administered intravenously. In this subgroup of patients, the 
low BG value (53.99mg/dL) was observed one hour after initial insulin 
infusion (plus bolus) was administered; this indicates that the insulin amount 
suggested by the protocol (initial insulin plus bolus dose) may be higher than 
required (i.e. overdose). This is perhaps in line with what YIIP intends to 
achieve - YIIP is initiated when the patient’s BG level is above 200mg/dL and 




Figure 3.1: Performance of hourly monitoring YIIP on 577 unique patients 
generated using Parker model (with meal disturbances) with normal initial 
condition 




































Figure 3.2: Performance of hourly monitoring YIIP on 577 unique patients 





However, the 577 unique patients considered in this study have an 
initial BG value of 150mg/dL or less. Therefore, the YIIP should be suitably 
modified by decreasing the initial bolus for patients who are initially in the 
hyperglycemic range but with BG values less than 200mg/dL.  
The performance of meal disturbance rejection of YIIP on 81 
constituted patients using Fabietti model is presented in Figure 3.3.From the 
results of applying YIIP on Fabietti model type patients (Figure 3.3), we find 
that all 81 patients have BG peak values in excess of 139mg/dL with the 
highest value being 289.52mg/dL. The BG values of 7 patients (8.64%) enter 
into hypoglycemic zone (<60mg/dL) with the lowest BG value reaching 
54.13mg/dL. In Fabietti patients, hypoglycemic episodes are not observed 
after the initial insulin infusion but are seen much later.  
 
 
































Figure 3.3: Performance of hourly monitoring YIIP on 81 constituted patients 
generated using Fabietti model with meal disturbance 
 
These studies show that YIIP should be tailored if it has to be applied 
for both Parker and Fabietti type T1D patients. We conclude that the initial 
insulin infusion (with/without bolus) amount should be optimized for better 
and safe treatment of a broad range of T1D patients, particularly if dextrose 
infusion is not practical or intended. This is why the MODYIIP was conceived 
of. The performance of MODYIIP is tested next. 
 
3.7 Results and Discussion:  MODYIIP on T1D Patients 
 The performance of MODYIIP is studied on the Parker and Fabietti 
models. The performance of the MODYIIP procedure on the Parker model 
patients with initial hyperglycemia (around 150 mg/dL) is expected to be good 
since Parker model patients were used to construct the procedure. The 
performance of MODYIIP on the entire cohort of Parker model type patients, 
the nominal patient and the worst-case patient are shown in Figures 3.4, 3.5 
and 3.6 respectively.  
In order to compare the results of the proposed strategy with those 
obtained with conventional control, the work of Ramprasad et al. (2004) is 




























used as the reference. Their work employed PID controller for blood glucose 
control in T1D patients and employed different tuning methods. They obtained 
best results with Shen (2002) tuning method, avoiding hypoglycemia 
(<60mg/dL) in all but 5% of the 577 virtual patients constituted from Parker et 
al.’s model. Frequent sampling (once every 4 min) was used for glucose 
measurement according to current glucose sensor technology. In comparison, 
MODYIIP (without external glucose infusion) with one hour sampling interval 
is able to avoid hypoglycemia (< 60mg/dL) successfully with a simple rule-
based protocol; however, the occurrence of hyperglycemia (> 140mg/dL) 
could not be avoided.  
 
 
Figure 3.4: Performance of hourly monitoring MODYIIP on 577 unique 




It is seen that hypoglycemia (under 60mg/dL) can be avoided 
successfully without extra glucose for all Parker model patients as expected. 
Note that, in Figure 3.4, Parker model patients with initial hyperglycemia is 
considered while in Figure 3.5 and 3.6, patients with a “normal” initial 
condition (BG around 81mg/dL) are considered.  
































Figure 3.5: Comparison of BG profiles of MODYIIP (magenta solid line) and 
original YIIP (blue dashed line) on nominal patient (Parker model type) with 





Figure 3.6: Comparison of BG profiles of MODYIIP (magenta solid line) and 
original YIIP (blue dashed line) on worst case patient (Parker model type) 
with normal initial condition  
 
































































It is seen that, for the worst-case patient, the original YIIP requires 
infusion of glucose to avoid hypoglycemia. Comparable results were obtained 
for nominal patient and worst-case patient with MODYIIP. For the worst-case 
patient, hypoglycemia (low BG value = 56.7mg/dL) with original YIIP could 
be avoided by MODYIIP (lowest BG value = 75.93mg/dL) with less dosage of 
insulin (50% of original YIIP initial insulin infusion) and no extra glucose. 
This shows the efficacy of MODYIIP. 
The effect of MODYIIP on the cohort of Fabietti model type patients is 
shown in Figure 3.7. There are no hypoglycemic episodes (lowest BG value is 
73.73mg/dL). All 81 patients enter into hyperglycemic zone (> 139mg/dL) 
with the highest BG peak value turning out to be 317.14 mg/dL.  
 
 
Figure 3.7: Performance of MODYIIP on 81 constituted patients generated 




The performance of modified YIIP on nominal and worst-case patients 
of Fabietti model type is shown in Figure 3.8 and 3.9 respectively. In both 
cases, the dangerous hypoglycemia is avoided successfully without external 
glucose.  
































Figure 3.8: Performance of YIIP (blue dashed line) and MODYIIP (magenta 






Figure 3.9: Performance of YIIP (blue dashed line) and MODYIIP (magenta 
solid line) on worst-case patient using Fabietti model with meal disturbance 
 
































































As can be seen in Figure 3.8, comparable BG profiles are obtained for 
nominal patient using both YIIP and MODYIIP; however, MODYIIP uses less 
insulin as compared to YIIP (MODYIIP uses 88.01U while YIIP uses 102.53U 
of insulin over a period of 72 hours). For the worst-case patient, YIIP uses 
both insulin and glucose liberally as compared to MODYIIP which uses a 
moderate amount of insulin but no external glucose.  
Canonico et al. (2006) used a PID-type controller named Proportional-
Derivative-2nd derivative (PDD2) controller and tested it on virtual patients 
constituted from T1D patient model of Fabietti et al. (2006). Their work 
employs frequent measurement of blood glucose concentration but the actual 
frequency was not mentioned. Compared to their work, the use of MODYIIP 
shows no hypoglycemia even with infrequent BG sampling interval (1 hr.). 
These results show that MODYIIP is a simple to implement protocol for the 
effective control of blood glucose levels in T1D patients; it has the potential to 
avoid the dangerous hypoglycemia without using external glucose infusion 
and with relatively infrequent sampling of blood glucose. Some further 
tailoring of the MODYIIP protocol is still needed to achieve tight glucose 
control. 
 
3.7.1 Validation of Modified YIIP on Bergman Model 
As one other verification of the effectiveness of the MODYIIP 
protocol, the Bergman model (Lam et al. 2002) with three meal disturbances 
(20g breakfast, 50g lunch and 40g dinner at 7am, 12 noon and 6pm) was 
simulated. Different meal amounts are considered here so as to evaluate the 
disturbance rejection capability on any realistic meal amount (which may vary 
from time to time for breakfast, lunch and dinner) and also to find out the 
relative performance of MODYIIP over other similar works conducted by 
other researchers. The Fisher meal model (Fisher, 1991) was used along with 
the Bergman model to simulate meal dynamics.  
Figure 3.10 compares the BG profiles obtained when one applied 
MODYIIP and YIIP on the nominal Bergman’s diabetic patient model with 
initial condition characterized by BG being 81mg/dL. The total insulin used by 
MODYIIP is 72.03U while that of YIIP is 58.01U and total extra glucose 
54 
 
amount used by YIIP is 87.5g for 72 hours Although no dangerous 
hypoglycemia (<45mg/dL) is observed in both cases, exogenous intravenous 
dextrose infusion was needed in original YIIP while it is not required in 
MODYIIP. Interestingly, MODYIIP shows a lowest BG value of 76.04mg/dL 
with no exogenous intravenous dextrose infusion compared to the lowest BG 
value of 52.82mg/dL obtained with YIIP which also needs exogenous 
intravenous dextrose infusion. MODYIIP results in a high BG value of 
288.31mg/dL compared to that of 253.73mg/dL obtained with original YIIP.  
 
Figure 3.10: Comparison of BG profiles of MODYIIP (magenta solid line) and 
original YIIP (blue dashed line) on nominal patient (Bergman model type) 
with normal initial condition 
 
Dua et al. (2004) used the same diabetes patient model to calculate 
optimal insulin infusion values off-line as an explicit function of the current 
blood glucose concentration of the patient. This approach has the advantage of 
using simple function evaluations for calculating insulin infusion and minimal 
on-line computation. The Bergman ‘minimal model’ was used as a patient and 
the sampling time of 5 min (compatible with the then glucose sensor 
technology) was used. A model predictive controller with the objective 
function that minimizes a quadratic function of state variables and insulin 
infusion rate with constraints on glucose concentration (60~120mg/dL) and on 

































insulin infusion rate (0~100 mU/min) was solved using multi-parametric 
quadratic programming (mp-QP). In the work of Dua et al. (2004), which uses 
the same diabetes patient model, meal model and meal amount as in this study, 
the highest BG value is about 350mg/dL. As noted earlier, MODYIIP shows 
the highest BG value of only 288.31mg/dL without hypoglycemia employing a 
simple rule-based strategy. Thus MODYIIP emerges as an effective strategy 
for BG control in T1D patients. The performance comparison of MODYIIP 
and YIIP on nominal Bergman model type patient with initial hyperglycemic 
condition (of about 330mg/dL) is shown in Figure 3.11. The hypoglycemic 
(<60 mg/dL) episode can be avoided successfully with lowest BG value of 
73.11mg/dL but with not much severe postprandial hyperglycemic BG peak of 
294.76mg/dL.   
 
Figure 3.11: Comparison of BG profiles of MODYIIP (magenta solid line) and 
original YIIP (blue dashed line) on nominal patient (Bergman model type) 




The performance of MODYIIP on the worst-case Bergman model 
patient using Bergman model is shown in Figure 3.12 and 3.13 for normal and 
hyperglycemic initial condition respectively.  


































Figure 3.12: Comparison of BG profile of MODYIIP (magenta solid line) and 
original YIIP (blue dashed line) on worst-case patient (Bergman model type) 




Figure 3.13: Comparison of BG profile of MODYIIP (magenta solid line) and 
original YIIP (blue dashed line) on worst-case patient (Bergman model type) 
with initial hyperglycemic condition  
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The dangerous hypoglycemia (<45mg/dL) is avoided by using 
MODYIIP, with the lowest BG being 59.39mg/dL and 62.8mg/dL; the total 
insulin used by MODYIIP is 61.01U and 61.5U while YIIP uses 72.52U and 
73.5U for normal and hyperglycemic initial condition respectively. In 
addition, YIIP uses 200g and 175g of total extra glucose during the 72 hours 
for normal and hyperglycemic initial conditions respectively.  
Thus, the MODYIIP protocol that was developed using Parker’s model 
is effective even on Bergman model type patients proving its robustness and 
versatility. 
 
3.7.2 Validation of Modified YIIP on Hovorka Model 
Next, a simulation study is performed to study the meal disturbance 
rejection capability of original YIIP and modified YIIP for a 60g carbohydrate 
meal using nominal Hovorka model (Hovorka et al. 2004 and Wilinska et al. 
2005). The 60g meal is given after one hour of the initial insulin infusion. The 
external insulin is infused through subcutaneous route and BG values are 
measured at 4 min sampling interval. The result of applying original YIIP on 
nominal patient of Hovorka type can be seen in Figure 3.14.  
 
Figure 3.14: BG profile with YIIP on nominal patient (Hovorka model type) 
with normal initial condition  

































The YIIP maintains the BG value above 60mg/dL by using frequent 
intravenous glucose infusion; the total insulin used by MODYIIP is 11.57U 
while that of YIIP is 12.47U and total extra glucose amount used by YIIP is 
137.5g for 18 hours. The maximum BG value is 256.99mg/dL. Thus, the YIIP 
gives acceptable performance. With MODYIIP, the result is as shown in 
Figure 3.15; it is seen that BG values can be maintained in the range (45-
257mg/dL). The low BG value is definitely a concern although the 
hypoglycemia (above 45mg/dL) is not considered to be fatal. 
 
Figure 3.15: BG profile with MODYIIP on nominal patient (Hovorka model 
type) with normal initial condition  
 
The performances of YIIP and MODYIIP on nominal Hovorka model 
patient with initial hyperglycemia of about 122mg/dL are shown in Figure 
3.16 and 3.17 respectively. 
It could be concluded that MODYIIP can cope well with the initial 
hyperglycemia as per results shown in Figure 3.17 with lowest BG and peak 
BG being 47.2mg/dL (hypogmic condition above 45mg/dL is not considered 
to be fatal) and 322.9mg/dL while YIIP resulted in 70.75mg/dL and 
285.05mg/dL respectively using extra glucose 100g during 18 hours as shown 
in Figure 3.16.  


































Figure 3.16: BG profile with YIIP on nominal patient (Hovorka model type) 






Figure 3.17: BG profile with YIIP on nominal patient (Hovorka model type) 
with initial hyperglycemic condition  

































































 These results show that MODYIIP is a possible candidate in treating 
T1D with simple and effective protocol. 
    
3.8 Conclusions 
The investigation conducted here shows that the YIIP may be modified 
and employed beneficially for blood glucose control in T1D patients. The 
original YIIP is tailored by modifying the amount of initial insulin infusion 
and bolus and by avoiding external glucose infusion – this results in a 
modified YIIP (MODYIIP) scheme. According to the results presented here, 
hypoglycemia (under 60mg/dL) can be successfully avoided with MODYIIP 
for all virtual T1D patients generated using Parker’s model and Fabietti’s 
model.  On the Hovorka’s model based nominal patient, MODYIIP results in a 
low BG value of 45.1mg/dL with initial BG at 81mg/dL– this is a cause of 
concern but may not lead to fatal consequences according to medical literature 
(Alsahli & Gerich, 2010). It is hoped that the MODYIIP scheme which is 
based on simple rules would be effective for BG control of T1D patients 
making it easy to implement in micro-implantable devices. Hyperglycemia 
(>180mg/dL) is tolerated so as to avoid hypoglycemia. Further studies could 
be performed for the modification of insulin infusion amount in MODYIIP so 
as to avoid high BG value (>180mg/dL) in T1D patients. Further studies could 
be performed for the modification of insulin infusion amount in MODYIIP so 
as to avoid high BG value (>180mg/dL) in T1D patients. In the meantime, to 
avoid hypoglycemia (that is evident in Hovorka model patient but it is not fatal 




Blood Glucose Regulation in T1D Patients: Classification Using 
Principal Component Analysis and Treatment Using Tailored 
Modified YIIP 
 
4.1 Background   
The blood glucose (BG) response to insulin and glucose varies from 
patient to patient (inter-patient variability) and even within a patient from time 
to time (intra-patient variability). The range of the response can be quite wide 
when one considers a cohort of patients. This raises the question: would be 
worthwhile and possible to classify patients into groups and tailor YIIP to each 
of these groups? In Chapter 3, YIIP was applied to control BG level in T1D 
patients and a modified YIIP scheme was also suggested with a view to avoid 
hypoglycemia (< 60mg/dL). The modified YIIP was developed based on the 
“patients” developed using the model of Parker et al. (2000), and was 
validated on cohorts of patients generated using Fabietti and Bergman models 
as well as on the nominal “patient” of the Hovorka model. It was observed that 
the modified YIIP algorithm was quite successful in avoiding hypoglycemia 
except in the case of the Hovorka “patient”. However, some patients did enter 
the hyperglycemic zone (> 180mg/dL) in postprandial condition. These results 
suggest that further modifications to the YIIP scheme are required, to make it 
effective in regulating BG levels in T1D patients. This objective is taken up in 
the present chapter where we develop a control strategy that is based on 
classification of patients into groups using Principal Components Analysis 
(PCA) followed by tailoring of YIIP to each of these groups. The goal is to 
regulate BG level in T1D patients in the range 60mg/dL < BG < 120mg/dL (in 
fasting condition) and 60mg/dL < BG < 180mg/dL (in postprandial condition).   
 
4.2 Motivation and Objectives 
As pointed out earlier, developing an algorithm that is effective and yet 
simple to implement will be helpful to treat T1D patients. YIIP (or its 
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modified version) is indeed easy to implement but its effectiveness in 
preventing hypo- and hyperglycemia needs to be improved further. The large 
uncertainty that one has to deal with in a single algorithm can perhaps be 
partitioned into smaller chunks of uncertainty via the grouping of patients into 
different classes and tailoring a control scheme (YIIP) for each of the classes. 
Such an approach can be expected to result in improved BG regulation in 
patients. 
The patient’s classes should be differentiated by their own intrinsic 
nature i.e. each class of patients should have similar intrinsic response to 
exogenous glucose and insulin. This information could be extracted from a 
suitable experiment or test (protocol). The experimental data for classification 
should be obtained from presently available diagnostic tests and the 
classification test should be simple for application in a clinical setting. These 
motivate us to continue our study in which YIIP will be used as the control 
algorithm but tailored for different classes of patients to achieve tight BG 
control. Our objective here is: (i) to develop a PCA-based methodology in 
which patients are classified into different classes based on data collected from 
a standard clinical protocol and (ii) to tailor YIIP for these different patient 
classes to meet the requirement of tight BG control (60mg/dL<BG<120mg/dL 
in fasting condition and 60 mg/dL < BG <180 mg/dL in postprandial 
condition). 
 
4.3 Clinical Diagnostic Test for Patient Classification 
Selection of an appropriate diagnostic test to use for developing the 
patient classification methodology is important. The chosen test should be 
simple and applicable in clinical setting. Already, several tests exist for the 
clinical diagnosis of diabetes – these include: (i) Oral Glucose Tolerance Test 
(OGTT), (ii) Fasting Plasma Glucose (FPG) test, (iii) Random Blood Glucose 
(RBG) test, (iv) Intra-Venous Glucose Tolerance Test (IVGTT), and (iv) 
Modified Intra-Venous Glucose Tolerance Test (MIVGTT). Among them, the 
MIVGTT is chosen because it is designed to observe both glucose and insulin 
dynamics with a single test. In MIVGTT, 0.3 g/ (kg body mass) of glucose is 
given for 1 min at the start and 0.02 U/ (kg body mass) of insulin is infused 
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after 20 min for a period of 5 min. Though the original MIVGTT needs 2.5 to 
3 hours to complete and several BG measurements are taken along the way, 
we assume that both BG and Plasma Insulin (PI) measurements available once 
every 20 min during the first hour would be enough for our designed test. The 
setting of the duration of the test for one hour is to ensure that hypoglycemia 
(< 60 mg/dL) is avoided during the test. This makes the test very feasible for 
application in a clinical setting. The fasting condition (after 8 hours of 
overnight fasting), in which 0.1 mU/L < PI <25 mU/L and 
70mg/dL<BG<300mg/dL, is required for our designed test. Note that the 
fasting PI is lower than 17 mU/L and the fasting BG is 70~99 mg/dL in 
normal individuals (Esoterix, 2010).  
After the test, the patients are offered meal or glucose depending on the 
last recorded BG value – this is required because the exogenous insulin 
administered during the test could lower BG to an undesirable level after the 
test. According to our simulations, the test appears to avoid dangerous 
hypoglycemia during the test.  
 
4.4 PCA as a Classification Tool  
Multivariate statistical tools are efficient for exploratory multivariate 
data analysis and classification. While several methods exist, PCA is chosen 
for its simplicity and effective classification efficiency. The application of 
PCA is well known for fault diagnostics in the chemical and process 
industries; it has also found applications in several domains of natural and 
social sciences. The primary application of PCA is as a dimension reduction 
tool to construct information rich, uncorrelated pseudo-variables (or prominent 
principal components) from a larger set of correlated variables. The principal 
components are arranged by their eigenvalues with principal components 
associated with larger eigenvalues being the most significant. Thus the first 
principal component is associated with the largest eigenvalue and captures the 
maximum variation from the data set. Successive principal components 
capture successively less variance and, by construction, they are orthogonal to 
the earlier principal components.  
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 Eigenvalue decomposition (EVD) of covariance matrix or singular 
value decomposition (SVD) of data set can be used to generate the principal 
components. The data set should be standardized (e.g. auto-scaled i.e. mean-
centered and variance-scaled) before the EVD or SVD so that the variables 
that have large values (based on measurement units) do not dominate the 
principal components. The PCA calculation (based on SVD of the data matrix) 
is described briefly below. 
• Auto-scaling of Variables               
( ). / ( )Z X X std Xµ= −                                            (4.1) 
• SVD of the auto-scaled data matrix Z 
[ , , ] ( )U V svd Zσ =                                              (4.2) 
• Score Matrix or Principal Component Matrix can be obtained by    [𝑆𝑐1,𝑆𝑐2, … ] = 𝑍 ∗ 𝑉                                         (4.3) 
The PCA model is characterized by the scores matrix T and the 
loadings matrix V wherein it is noted that only the first ‘k’ prominent principal 
components are retained. Therefore, we may write 𝑍 =  𝑇𝑘𝑉𝑘𝑇 where Tk and 
Vk contains only the first k columns of T and V.  
When new data Xnew arrives, it is first scaled in a manner consistent 









=                                                    (4.4) 
Then PCA projection of the new data can be described by 
𝑡𝑛𝑒𝑤 =  𝑋𝑛𝑒𝑤,𝑆 ∗ 𝑉𝑘                                               (4.5) 
 
4.5 Details of the Study 
      The ability of the control algorithm in meeting the desired control 
objectives should be tested on a cohort of patients. For our purpose, the model 
proposed by Fabietti et al. (2006) is chosen and its dominant parameters are 
perturbed by ± 70% of their nominal values to generate the patient cohort (the 
same procedure as mentioned in section 3.4 is applied here as well to produce 
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the cohort of patients). The control algorithm is developed by two steps viz. 
(1) patient classification using PCA and (2) tailoring of YIIP for each class of 
patients. The details of both these steps will be described in sections 4.5.1 and 
4.5.2 respectively. In all the simulation studies here, measurement noise of 
about 17% has been added to the true blood glucose values. Input constraint 
has not been considered in the case studies. However, the lower bound for 
inputs (meal and insulin) is set to zero so as to keep the simulations physically 
meaningful.  
 
4.5.1 Patient Classification Using PCA 
      The PCA model is developed based on the simulated experiments. 81 
simulated patients (using Fabietti’s Model) who meet the conditions as 
specified in section 4.3 are given our designed MIVGTT for one hour so as to 
extract the intrinsic characteristics of each patient. The response of each 
patient to given intravenous glucose input (given at the start of experiment) 
and exogenous insulin infusion input (given at the 20th min of experiment) are 
measured by collecting BG and PI measurements once every 20 min. Similar 
experiments for this patient cohort are run for 10 times with different random 
initial values of BG and PI (at the start of the experiment) but within the range 
of prescribed conditions. This helps to generate a larger patient cohort – thus 
many patients in the generated database will have similar parameters but, 
depending on their initial conditions, their response to the MIVGTT will vary 
considerably. The PCA model is developed based on the collected data.  
Then the primary model is developed based on the above mentioned 
simulated experimental data with the help of PCA using information given by 
PI measurement data matrix (81 patients ×10 runs and four measurements 
each). The BG measurements are taken only to ensure that the patient does not 
experience hypoglycemia but are not used in the PCA model. Pre-processing 
of the data is performed by removing the linear trends using least squares - this 
helps to improve the classification efficiency by minimizing the effect of 
initial BG and PI values. Then, the variance scaling of each column is done so 
as to provide each variable (column) the same degree of importance in the 
PCA model. The preprocessed data set is then used to construct the PCA 
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model. When new patient data is obtained, the data is subject to consistent data 
pre-treatment and the patient is classified by projecting the data onto the 
present model (or onto present patient classes). More details on the PCA 
models will be provided later. 
 
4.5.2 Tailoring YIIP for Patient Classes 
Individualization of the treatment protocol for each patient can be very 
time consuming and such individualized protocols, even if generated, may 
lack the required robustness when faced with parametric uncertainties and 
variations. For this reason, the collected MIVGTT data is used to generate 
specific classes of patients and the YIIP is optimized for each class of patients. 
The optimized solution for each patient class should provide robust 
performance for patients within that class. 
We seek to modify the YIIP for each patient class in such a way that 
the initial insulin infusion will be optimized and followed by the original YIIP 
based insulin infusion. These modified class-based protocols would be 
generated via the formulation of an optimization problem with suitable cost 
function and constraints.  The optimization problem is set up to find the best 
initial insulin infusion amount for the YIIP on a “normal” day (with three 
meals) in which BG is controlled with the following three objectives: (i) BG 
not to exceed 180mg/dL in postprandial condition, (ii) BG not to enter the 
dangerous hypoglycemic region (<60mg/dL), and (iii) minimize the maximum 
value of BG following each meal. The schematic representation of the 
optimization problem is demonstrated in Figure 4.1 where ‘𝑥’ represents the 
initial insulin infusion amount. The need for larger insulin infusion amount to 
meet objectives (i) and (iii) conflicts with the requirement of objective (ii) 
which is to use the minimum amount of insulin required to avoid 
hypoglycemia. The three objective functions are linearly combined with equal 
weight into a single objective function. Similar optimization problems are set 
up for each class of patients obtained from the classification process and are 
solved separately. The optimal solutions obtained from the formulated 
optimization problems would serve as the initial insulin infusion amount for 




Figure 4.1: Schematic of the Optimization Algorithm 
 
The mathematical description of the optimization problem for a class 
of patients can be described as follows. The output BG values for patient 𝑖 
over the time 𝑡, 𝐵𝐺𝑖(𝑡), which is function of insulin infusion and meal 
disturbance are described as 
𝐵𝐺𝑖(𝑡) = ℎ𝑖�𝑢(𝑡),𝑑(𝑡)�.                                                    (4.6) 
Where, 
𝑡 = time interval from 0 to 𝑡, 
𝑢(𝑡) = the rate of insulin infusion over the time 𝑡, 𝑢(𝑡) = 𝑓(𝑥,𝑌𝐼𝐼𝑃),  
𝑥 = initial insulin infusion,  
𝑌𝐼𝐼𝑃 = original YIIP based insulin infusion that followed 𝑥,                                                     
𝑑(𝑡) = the meal disturbance over the time 𝑡, 𝑑(𝑡) = 𝑔(𝑀),  
𝑀 = meal (three meals in a normal day).                                                                         
The highest BG value, ℎ𝑠𝑡𝐵𝐺 and lowest BG value, 𝑙𝑠𝑡𝐵𝐺 for a class of 
𝑛 patients are:                         
                                    ℎ𝑠𝑡𝐵𝐺 = max ��𝐵𝐺𝑖(𝑡)�𝑛� 
and                                             𝑙𝑠𝑡𝐵𝐺 = min ��𝐵𝐺𝑖(𝑡)�𝑛�. 
The three objective functions are considered as 
𝑜(𝑥) = ℎ𝑠𝑡𝐵𝐺 − 180 
where,                                     𝑜(𝑥) > 0                                                       (4.7) 
𝑝(𝑥) = 60 − 𝑙𝑠𝑡𝐵𝐺 
where,                                     𝑝(𝑥) > 0                                                       (4.8) 
  Insulin infusion 













and         𝑞(𝑥) = ℎ𝑠𝑡𝐵𝐺.                             (4.9) 
These functions are combined into a single objective function with equal 
weight for a nonlinear optimization problem as  
𝑚𝑖𝑛
𝑥 (𝑜(𝑥) + 𝑝(𝑥) + 𝑞(𝑥))2                                         (4.10) 
with constraint  𝑥 ≥ 0 . 
The best value of 𝑥 for the patient class is found by optimizing the BG 
values to be in the range 60~180 mg/dL with the objective function (equation 
4.10). Note that the initial insulin infusion (𝑥) has significant effect on BG 
control in YIIP and its requirement for fine tuning (in Chapter 3), and thus 𝑥 is 
considered as the decision variable here. The constraint that 𝑥 is greater than 
or equal to zero is set in order to avoid negative values. The function 𝑜(𝑥) is 
for BG not to exceed 180 mg/dL in postprandial condition,  𝑝(𝑥) is for BG not 
to enter the dangerous hypoglycemic region (< 60 mg/dL), and 𝑞(𝑥) is to 
minimize the maximum value of BG following each meal. 
 
4.6 Results and Discussion 
 We present the results and discussion for this study in three parts: (1) 
PCA results on patient classification (section 4.6.1), (2) tailored YIIP and its 
results (section 4.6.2) and (3) validation of the developed algorithm on other 
patient models (section 4.6.3). 
 
4.6.1 PCA Results on Patient Classification 
           After applying PCA directly onto the (810×4) data set (explained 
earlier) without removal of linear trends, 9 patient classes are obtained as 
shown in Figure 4.2. It is confirmed, via matching each point in the PCA score 
plot with the assigned experiment number (i.e. each patient), that each line 
represents a single patient group. However, it would be useful to have these 
groups segregated in the PCA score space if we were to use the scores plot to 





Figure 4.2: Patient classes obtained from PCA without data pretreatment with 









Figure 4.3: Patient classes obtained from PCA with data pretreatment with 
99.99% confidence interval 
































































When the linear trend is removed from each data sample and PCA of 
the resulting data set is performed, the results are as shown in Figure 4.3. It is 
seen that the segregation is much better now with only classes 5 and 9 
overlapping significantly. With the linear trend removed from each data 
sample, PCA explains 85.25% of the variance in the data set with the 1st 
principal component and 100% of the variance with the first two principal 
components. The total of 810 points resulted from 10 runs (different initial BG 
and PI values for each run) of MIVGTT for each of the 81 patients (mentioned 
in section 2.6 with 70% variation in patient parameters considered) shows up 
in Figures as 9 patient classes (each class consists of 90 points). 
The loading Plot of PCA without pretreatment and with pretreatment 
(shown in Figure 4.4 and 4.5 respectively) show the presence of three clusters 
in the variable space. This indicates that three measurements (one taken out of 
each of these clusters) may be sufficient information in order to characterize 
the patients. This insight may be useful in designing measurement protocols 




Figure 4.4: Loading Plot obtained from PCA without data pretreatment 































4.6.2 Results with the Tailored YIIP  
 The single variable optimization (SVO) problem of finding out the best 
initial insulin infusion amount (defined by ‘𝑥’ in Figure 4.1) for the 9 patient 
classes is solved by the Nelder-Mead Simplex Search method. For this SVO 
problem, the simplex search reduces to a line search. MATLAB’s (version 7.6, 
2008a) built-in algorithm for unconstrained optimization ‘fminsearch’ is 
employed to solve this optimization problem for each patient class.  
Positive values between 0 and 10 are provided as initial guess values of 
‘𝑥’. The algorithm converged to the optimal values in each case for the default 
tolerance in the ‘fminsearch’ algorithm. The 𝑙𝑠𝑡𝐵𝐺 and ℎ𝑠𝑡𝐵𝐺 values in the 
functions 𝑜(𝑥) 𝑎𝑛𝑑 𝑝(𝑥) are changed to 67mg/dL and 177mg/dL (instead of 
60mg/dL and 180mg/dL) to avoid hypo- (<60mg/dL) and hyper- (>180mg/dL) 
glycemic condition. The optimal values of ‘𝑥’ and the highest & lowest BG 
values of each of the 9 classes are summarized in Table 4.1. 
























Table 4.1: Summarized results of tailored YIIP for all patient classes 
 





1 6.99 67.00 178.86 
2 2.05 67.82 178.88 
3 1.14 64.83 179.46 
4 6.87 61.23 182.64 
5 2.03 60.55 182.67 
6 1.02 60.10 186.04 
7 7.38 60.68 181.04 
8 2.21 59.01 180.99 
9 1.06 59.31 184.16 
 
 
Figure 4.6 through 4.14 demonstrate the effectiveness of tailored YIIP 
on T1D patients on a normal day comprising of three meals (taken at 7 AM, 
12 Noon and 6 PM) with 20 g, 50 g & 50 g carbohydrate content respectively. 
Based on the optimal values of ‘𝑥’, the 9 classes can be further reduced into 3 
groups. The values of ‘𝑥’ for Group I (Class 1, Class 4 & Class 7) are higher 
than those of Group II (Class 2, Class 5 & Class 8) which are higher than those 
for Group III (Class 3, Class 6 & Class 9). Going forward, the results will be 
discussed based on these three groups. 
 
 
4.6.2.1 Results of Tailored YIIP for Group I 
Group I (Classes 1, 4 and 7) patients have BG values in the range of 
(60~183mg/dL) - the corresponding illustrations are shown in Figure 4.6, 4.7 
and 4.8 respectively. Hypoglycemia (<60mg/dL) is seen to be avoided 
successfully. Class 7 patients require the highest initial insulin amount among 
this group.  
Analysis of the parameter values reveals that this group has the same 
insulin diffusion rate value (Ki=3.03e-3mL/hr), which is also the lowest 
among all groups (nominal Ki=0.0101mL/hr). The time constants of insulin 
diffusion in the plasma compartment (Txi) are 0.543hr, 1.81hr and 3.077hr for 













Figure 4.7: Tailored YIIP result for Class 4 Patients 
 




















































































4.6.2.2 Results of Tailored YIIP for Group II 
 Blood glucose values for Group II (Classes 2, 5 and 8) patients lie in 
the range between 59mg/dL and 183mg/dL. The profiles of BG, insulin 
infusion, meal ingestion and intravenous glucose infusion for these three 
classes are shown in Figure 4.9, 4.10 and 4.11 respectively. Here again, 
hypoglycemia (BG < 60mg/dL) is avoided for classes 2 and 5 patients and 
only marginally violated for class 8 patients. Analysis of the parameter values 
for this patient group reveals that this group has the same insulin diffusion rate 
(Ki) values. Specifically, Ki (0.0101mL/hr) value for this group can be 
regarded as medium among the three groups. The time constant of insulin 
diffusion in the plasma compartment (Txi) for each class of this group is in the 
ascending order from the lowest to the highest with Class 8 patients having the 
highest Txi (0.543 hr., 1.81 hr. and 3.077 hr. for Classes 2, 5 and 8 
respectively). Class 8 patients require the largest initial insulin amount among 
this group to maintain BG in the acceptable range (60mg/dL<BG<180mg/dL). 
Thus it appears that the low time constant (Txi) value results in effective BG 
control with the tailored YIIP scheme.  
















































Figure 4.10: Tailored YIIP result for Class 5 Patients 



















































































4.6.2.3 Results of Tailored YIIP for Group III 
 The BG values for patients in Group III (Classes 3, 6 and 9) are 
between 59mg/dL and 187 mg/dL over the three simulated days - the 
corresponding plots are in Figure 4.12, 4.13 and 4.14 respectively. There is a 
tiny violation of the 60mg/dL hypoglycemia limit in the case of Class 9 
patients. Hyperglycemia is experienced in Classes 6 and 9 patients with Class 
6 patients exceeding the 180mg/dL limit by as much as 6 mg/dL.  
 Analysis of the parameter values shows that this group has the 
highest insulin diffusion rate (Ki = 0.01717mL/hr) value among all groups. 
This group also requires the lowest initial insulin amount among all groups. 
And the time constant of insulin diffusion in the plasma compartment (Txi) for 
each class of this group are in the ascending order from the lowest to the 
highest value with Class 9 patients having the highest Txi value (0.543hr, 
1.81hr and 3.077hr for Classes 3, 6 and 9 respectively).  


















































Figure 4.13: Tailored YIIP result for Class 6 Patients 















































































Figure 4.14: Tailored YIIP result for Class 9 Patients 
 
 
More detailed analysis of patient responses whose BG values exceed 
180mg/dL reveals that these patients have very low insulin sensitivity. Thus, 
insulin sensitivity can be regarded as a significant factor in the quality of BG 
regulation achieved with tailored YIIP. Class 6 patients require lowest initial 
insulin amount among all groups to maintain BG in the acceptable range 
(60mg/dL < BG < 180mg/dL). Overall, low time constant (Txi) value, high 
value for the plasma insulin distribution volume (Ki) and high insulin 
sensitivity result in better BG control as expected. 
 
4.6.3 Validation of Developed Algorithm on Other Patient Models 
As proof of the appropriateness and effectiveness of the classification 
based tailored YIIP algorithm, it is tested on patients created from the Parker, 
Bergman and Hovorka models. Three “patients” using nominal parameter 
values in the Parker, Bergman and Hovorka models were tested with the 
classification based tailored YIIP algorithm. The classification test performed 
on these three patients (after data pretreatment) indicates that all of them are 
classified as being similar to Class 3 patients (see Figure 4.15). Class 3 
patients require less initial insulin infusion amount compared to most other 








































classes (see Table 4.1). This result is consistent with the low basal insulin 
requirements of the Parker, Bergman and Hovorka models (with nominal 
parameters), and demonstrates the validity of the classification algorithm. 
Averaging of initial insulin infusion amount may be adopted and employed if 
a “tested patient” happens to fall in between the classes shown in Figure 4.15.  
 
Figure 4.15: PCA based classification of patients obtained from Parker, 




To test the effectiveness of the YIIP algorithm that was tailored for 
Class 3 patients of the Fabietti model, the three patients (generated from the 
nominal Parker, Bergman and Hovorka models) are challenged with the same 
carbohydrate intake over a 3-day period as was done earlier. The obtained 
results are plotted in Figure 4.16, 4.17 and 4.18 respectively. The resulting BG 
values are in the range of (50mg/dL < BG < 180mg/dL). For the Parker model, 
the minimum and maximum BG values were 81.08 mg/dL and 115.48mg/dL 
respectively. For the Bergman model the minimum and maximum BG values 
were 69.52mg/dL and 175.8mg/dL respectively while, for the Hovorka model, 
these values came out to be 51.28mg/dL and 116.16mg/dL respectively. The 
results indicate that the strategy does not lead to hyperglycemia for any of the 
patients.  













































Figure 4.17: Tailored YIIP result for Bergman Model nominal Patient 

































































The Hovorka patient enters the dangerous hypoglycemia region 
(BG<60mg/dL) which is a concern. It would appear that the algorithm must be 
further tuned to avoid hypoglycemia through the intravenous infusion of 
glucose – this “handle” is not utilized by the algorithm. Also, the BG profile of 
the Hovorka patient is oscillatory and its amplitude is also significant. The 
Bergman patients’ BG profile is also oscillatory but has a smaller amplitude 
and therefore not a real concern. 
 
4.7 Conclusions 
This chapter demonstrates the development of a novel BG regulation 
algorithm for T1D patients. It is based on a classification procedure that 
utilizes PCA to categorize the patient cohort into 9 classes which is further 
reduced into 3 groups. The YIIP algorithm was tailored for each of the classes 
through the optimal choice of initial insulin amount. Any new patient would 
be subjected to the MIVGTT and the test results would be projected on to the 
PCA scores chart to classify the patient into one of the nine classes. The YIIP 






























algorithm tailored for that class would be implemented on the patient. This 
approach showed very promising results on the Parker and Bergman patient 
but resulted in hypoglycemia on the Hovorka patient. More rigorous tests 
would be needed on a large cohort of patients generated out of these models to 
test the robustness of the proposed approach. The proposed approach to 
classification based BG control, has also identified opportunities to reduce the 
experiment time of the intravenous glucose tolerance test (IVGTT) as well as 
indicated that about 3 measurements should suffice during the experimental 




Control of BG Levels in T1D Patients using the Linear 
Modeling Error Compensator Approach 
 
5.1 Background  
 The design of robust controllers is necessary for the model-based 
control of processes that have significant uncertainties in their structure and/or 
parameter values. In the context of blood glucose control in diabetes patients, 
there is a need to design controllers that are robust against the unavoidable 
model-patient mismatch that arise due to the inter- and intra-patient variability.  
In the past, researchers have attempted to handle this problem in 
several ways; for example, systematic design of robust H∞ controller based on 
uncertainty characterization was pursued by Parker et al. (2000), and a 
simulation-optimization based approach was adopted by Ramprasad et al. 
(2004b). They established the applicability of their approach by showing how 
their robust controllers rejected meal disturbances on a cohort of virtual 
patients taken from within the uncertainty bounds. The positive and negative 
aspects of these approaches were presented in Chapter 2. 
 Further studies are needed in developing and testing the effectiveness 
of robust controllers for blood glucose regulation in T1D patients and reach 
the goal of attaining fail-proof artificial pancreas. This chapter aims to develop 
a strategy based on the linear modeling error compensation (LMEC) approach 
and examine its effectiveness in handling model uncertainties. 
 
5.2 Motivation and Objectives 
There is a need to examine alternative approaches that can handle 
uncertainties in patient models for blood glucose level control in T1D patients. 
What we need is a simple and yet effective algorithm that can help in this 
regard – linear robust controllers are therefore prime candidates for the 
purpose. Among robust controllers, the modeling error compensator has been 
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found effective in the control of chemical reactors (Alvarez-Ramirez, 2002) 
and in observer design for estimating bearing internal temperature and pre-
load of machine tool spindle (Tu and Stein, 1998). However, these studies 
involved nonlinear models.  Sun et al. (1994) proposed a linear modeling error 
compensator (LMEC) scheme which could be applied to handle uncertainties 
in linear models. Here, we wish to study the applicability of the LMEC 
scheme to regulate blood glucose concentration in T1D patients. Significant 
levels of uncertainty in patient model parameters for the different T1D models 
will be considered and LMEC controllers will be developed. The developed 
LMEC scheme will be tested on cohorts of virtual patients to determine its 
performance. 
   
5.3 Linear Modeling Error Compensator 
 In LMEC, a model reference controller is used for primary design and 
the parameter adaptation is using a compensator instead of on-line 
identification for estimation of system parameter(s) and tuning of controller 
parameter(s). The central idea of LMEC is to compensate for the error arising 
out of parametric uncertainty by determining the modeling error via plant 
input and output signals with known linear model order and using this 
information in the design. In addition to nominal feedback, another feedback 
loop is introduced using the modeling error and this feedback action is 
explicitly proportional to the parametric error which is the source of 
uncertainty. When no modeling error is present (i.e. the model parameter is not 
different from the nominal model), the compensator output becomes zero and 
the control scheme is then equivalent to the original model reference 
controller.  
 
5.3.1 Uncertainty Description 
The bounds for the uncertainty that represents inherent inter- and intra-
patient variability, is incorporated into the parameters of different diabetes 
patient models. Specific model parameters are perturbed by up to ±40% from 
their nominal values to obtain patient cohorts. Such an investigation helps to 
check the robustness of the LMEC and how its performance is when presented 
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with the inevitable model mismatch (details including those of the generated 
patient cohort are mentioned earlier in section 2.4). The controller is based on 
the linear transfer function approximation of the patient but the “true” patient 
is the nonlinear model. It is on the true patient that the LMEC based control 
algorithm will be tested. In this study, the models for controller design are 
obtained as second order transfer function approximations through a step test 
on the nonlinear model. The step response(s) are obtained by decreasing 
insulin infusion by 10% of its nominal value in the particular patient model. 
The bounds for uncertainty are determined from the parameters of the 
estimated linear second order transfer functions. 
 
5.3.2 LMEC Controller Design 































−                       (5.1) 
where )(sU = Laplace transform of the input, )(sY  = Laplace transform of the 
output.  
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For the nominal model,  00






Let       )()()( sRsMsYM =                                     (5.2) 
and                                       )()()( sRsGsY c=                                       (5.3) 
where )(sM  = reference model which gives the desired behavior of the 
closed-loop system, )(sR   = reference signal, )(sGc  = transfer function 
representing the closed loop system, )(sYM = desired system response, and 
)(sY  = closed loop system response. 
The control objective is to design a feedback controller which uses 
)(sR  and )(sY  to generate )(sU in such a way that )(sY  is as close as 
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possible to )(sYM  in the presence of parametric uncertainty in )(sG . The 















=                                   (5.4) 
in which )(0 sG is the nominal patient model bounded in )(sG , and )(0 sC  and 
























kk = , Mk = leading coefficient of Mz , 0pk = nominal value of pk , 
)(sΛ = a stable monic polynomial of degree 1−n , ( Mzα ), α  = a stable 
polynomial, )(),( 21 ss θθ  = polynomials of degree at most 2−n  and 3θ  = 
constant. 
 
             
  
Figure 5.1: Schematic of a feedback control system with modeling error 
compensation 
 
Equation (5.4) can be deduced from Figure 5.1 using lower loop (bold 
lines and painted blocks). 
For the actual plant, the controller parameters which are varying (i.e 
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Instead of solving equation (5.7), the parameters for the nominal plant 
are solved by (Λ − 𝜃1)𝐴0 − (𝜃2 + Λ𝜃3)𝐵0 = 𝑘𝛼𝑝𝑀𝐵0     (5.8) 
By multiplying equation (5.7) with �𝑀(𝑠)
Λ(𝑠)�𝑌(𝑠) and using the plant 
equation 𝐵(𝑠)𝑈(𝑠) = 𝐴(𝑠)𝑌(𝑠), one obtains 




𝑌 + 𝜃3∗𝑀𝑌.   (5.9) 
With the above scheme, robustness is not guaranteed against 
uncertainties that are present in the model )(sG . To achieve the robustness in 
the presence of parametric uncertainty, the modeling error signal )(sE  is 
defined by using the plant input and output signals and the information on 
)(sM  and )(0 sG . This signal reflects the difference between G  and 0G . 






21 θθθ                               (5.10) 
By using equation (5.9) for substitution of 𝑀𝑈 into equation (5.10), E is 








−= θθθθθθ .             (5.11) 
The proposed control law is    )( 100 EFYFRCU −−= .                             (5.12) 
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where q is an integer not less than mn − , and τ is a small positive time 
constant. τ is chosen for any frequency band ],[ ul ωω  (where lω  = lower 
frequency bound (0.00001 rad/s in this study) and uω = upper frequency bound 
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MH                            (5.18) 
hjH <)(1 ω                                               (5.19) 


































              (5.20) 
The bounds for 1θ , 2θ , 3θ  and k are determined by using the uncertainty bounds 
and the general theory of Diophantine polynomial equations. 
]},[);(inf{0 ulll ωωωω ∈=                                     (5.21) 
0)( >ωl                                                      (5.22) 
where 0≥> lu ωω  are finite. 
Thus, )(),(),( 100 sFandsCsF  are chosen to obtain the robust stability for any 
finite frequency band ],[ ul ωω  and to achieve the following performance 
specification: 
)()()( ωωω ljGjM c <− ,                ],[ ul ωωω ∈∀            (5.23) 
 
5.4 Details of the Study 
 The effectiveness of LMEC is evaluated in silico on a virtual cohort of 
T1D patients by perturbing the key parameters of the models by 40% i.e. we 
consider a ±40% uncertainty bound on the parameters. The LMEC controller 
algorithm is designed and its performance is evaluated on the chosen 
simulated T1D patient models (Bergman model, Parker model & Fabietti 
model). For performance evaluation, a normal day (with three meal 
disturbances: breakfast (10.8 g), lunch (50 g), and dinner (50 g) carbohydrate 
at meal times 7 am, 12 noon, and 6 pm respectively) was simulated. A bit 
different meal amount from previous chapters is considered here; again, the 
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meal amount can be different at any time. The intravenous route is chosen for 
insulin administration to negotiate these meal disturbances. 
 
5.5 Evaluation of Disturbance Rejection  
The performance of LMEC is evaluated on three chosen diabetes 
patient models (Bergman, Parker, and Fabietti models) by generating virtual 
patient cohorts based on these models. The desired set point considered in this 
study is 4.5mmol/L (or 81.1mg/dL). The performance of the proposed 
controller on the above mentioned three patient models is presented below.  
 
5.5.1 Analysis with the Bergman Model 
Uncertainty bounds are determined for the parameters p1, p2, p3 and n 
of this model. The nominal values of the four model parameters are given in 
Table 5.1 (P2_basalnominal). The performance analysis of the LMEC would be 
evaluated on several patients constituted via model parameter perturbations. 
The four model parameters (i.e., p1, p2, p3 & n) are perturbed by changing 
them by ±40 % of their nominal values. Each parameter has three levels (min, 
nominal, max) and the combination of four parameters resulted in 81 (= 34) 
virtual patients in this study.  
The parametric sensitivity analysis for these 81 combinations is done 
using their BG response to 10% decrease in their basal insulin requirements. 
Three patients with minimum, nominal, and maximum BG responses from the 
nominal BG value (81.08mg/dL) are chosen to determine the uncertainty 
bounds assuming that these three patients could cover the uncertainty bound of 
all 81 virtual patients. The parameter values of these three patients are 
presented in Table 5.1. The patient who has nominal basal insulin infusion 
represents the nominal patient of Bergman model. The nonlinear ODE model 
with parameter values given in Table 5.1 of these three patients) are perturbed 
by a 10% decrease in their basal insulin infusion and the corresponding step 
responses are obtained. Each of the obtained step responses is approximated 
by a second order transfer function without delay {κ / (τ1s+1) (τ2s+1)} and the 
values are shown in Table 5.2. The uncertainty bounds are obtained from these 
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three second order transfer functions in the form of {κp/ (s+β) (s+γ)} and the 
values of these parameters are shown in Table 5.2 also. The lower, nominal & 
and upper uncertainty bounds {(κpl, βl, γl), (κp0, β0, γ0) & (κpu, βu, γu)} are 
marked as in Table 5.3. The reference model (M) is defined to be second order 
critical damping system of unit gain {M(s) = 1/(τM2s2+2τMs+1): 𝜏𝑀 =
√𝜏1𝜏2/2} using τ1 & τ2 of nominal patient from Table 5.2. This model M(s) is 
converted into unit time constant form and is denoted as {M(s) = zM(s)/pM(s)}. 
To design the controller C0(s) and F0(s), {Λ(s) = (s+1)}, n = 2, m = 0, kM = zM, 
and (k*=kM/kpu) are defined. The θ1(s), θ2(s) and θ3(s) are determined using the 
general theory of Diophantine polynomial equations and nominal values of 
uncertainty bounds (κp0, β0, γ0). Similarly, the lower and upper bounds of θi(s) 
are estimated using lower and upper {(κpl, βl, γl) & (κpu, βu, γu)} uncertainty 
bounds. The values of θi are numeric values and are presented in Table 5.3. To 
define the F1(s), the time constant (τ) is estimated by trial and error using 
equations (5.10) to (5.22) to satisfy the equation (5.23).  
 
Table 5.1: Patient parameter values of nonlinear ODE model for chosen three 
Bergman model patients 
Patient (Pi) p1 p2 p3 n 
P1_basalmin 0.028735 ×1 .4 0.028344 × 1.4 5.035e-05 × 0.6 5/54 × 1.4 
P2_basalnominal 0.028735 0.028344 5.035e-05 5/54 
P3_basalmax 0.028735 × 0.6 0.028344 × 0.6 5.035e-05 × 1.4 5/54 × 1.4 
 
 
Table 5.2: Parameter values of estimated second order transfer functions for 
chosen three Bergman model patients 
Patient (Pi) κ τ1 τ2 κp  β  γ  
P1_basalmin -1.02 26.54 26.54 -1.44×10-3 3.77×10-2 3.77×10-2 
P2_basalnominal -4.94 38.74 38.74 -3.29×10-3 2.58×10-2 2.58×10-2 
P3_basalmax -19.39 78.98 78.98 -3.11×10-3 1.27×10-2 1.27×10-2 
 
 
The meal model proposed by Lam et al. (2002) which gives a more 
realistic BG response for a given meal compared to Fisher meal model is used 
as the disturbance model (see Appendix A. 2), and the rate of insulin infusion 
is bounded between [0, 100] mU/min. The performance results of LMEC 
controller on the nominal patient and the cohort of 81 patients are illustrated in 




Figure 5.2: Performance of LMEC on Bergman nominal patient model for the 
three meal disturbances (upper red dash-dot line: 180mg/dL, lower red dash-
dot line: 60mg/dL) 
 
 
Figure 5.3: Insulin infusion profile obtained with LMEC on Bergman nominal 
patient model corresponding to the meal disturbances 






































Figure 5.4: Performance of LMEC on a cohort comprising of 81 patients 
obtained from Bergman model (red dash-dot line: 60 mg/dL) 
 
 
Table 5.3: Parameter values for designed LMEC controller for Bergman 
Model  
[κpl  κp0  κpu] [-3.29 -3.11 -1.44] ×10-3 
[βl   β0  βu] [1.27 2.58 3.77] ×10-2 
[γl   γ0   γu] [1.27 2.58 3.77] ×10-2 
τ 0.51 
zM(s) 2.67 ×10-3 
pM(s) s2 + 10.33 ×10-2s + 2.67 ×10-3 
[θ1  θ2   θ2] [-5.16  -1489.30   1549.02] ×10-2 
 
 
The performance of designed LMEC on nominal patient is satisfactory, 
and BG values are in the range of 80~180mg/dL during the given three meals. 
The results of using LMEC on the patients generated with the Bergman model 
show that none of the 81 virtual patients enter the undesirable hypoglycemic 
region (<60mg/dL) and lowest glucose value reached is 72.81mg/dL. The 
highest BG value after meal reaches 213.93mg/dL, and is in the acceptable 
range although higher than 180mg/dL. It can be concluded that the 
performance of LMEC controller is satisfactory in the sense of avoiding 
hypoglycemia and maintaining reasonable BG profile through the day. It can 
also be concluded that defining uncertainty bounds using the deviation from 

































nominal BG value by 10% decrease in basal insulin is appropriate. In short, 
the LMEC with the careful specification of the uncertainty bounds is 
promising for BG control. 
 
5.5.2 Analysis with the Parker Model  
Parker et al. (2000) identified the set of eight patient model parameters 
(EIPGU-EГ, EIPGU-DГ, EGHGU-EГ, EGHGU-DГ, EGHGP-EГ, EGHGP-DГ, 
FPIC & FHIC) from amongst the 19 parameters by parametric sensitivity 
analysis. They noted that ±40% deviations in three parameters (EIPGU-EГ, 
EGHGU-EГ, and EGHGP-EГ) from their nominal values have significant 
resistance to insulin and glucose dynamics. Thus, these three parameters are 
assumed that they might almost cover the most uncertainty bounds and are 
chosen from the set of eight patient-specific parameters to determine the 
uncertainty bounds for the LMEC controller to avoid extensive numerical 
analysis. The combination of these three variables with three permutations of 
each variable (maximum limit, nominal value, minimum limit) results in 27 
combinations. The amount of insulin required to maintain the BG of each of 
these 27 patients at 81.1mg/dL (4.5mmol/L) is calculated.  
The “patients” that required the minimum, nominal and maximum 
insulin amounts to keep BG at 81.1 mg/dL (4.5 mmol/L) are chosen and their 
step responses by 10% reduction in basal insulin infusion are approximated by 
second order transfer functions. Similar methods and procedures to define the 
uncertainty bounds and designing the LMEC controller as in section (5.5.1) 
are applied here to design the LMEC controller for Parker model type patients. 
The parameter values for linear second order transfer functions and designed 
LMEC controller parameter values are provided in Tables 5.4 and 5.5 
respectively.   
 
Table 5.4: Parameter values of estimated second order transfer functions for 
chosen three Parker model patients 
 
Patient (Pi) κ τ1 τ2 κp β γ 
P1_basalmin -6.09 53.44 23.52 -0.48 ×10-2 1.87 ×10-2 4.25 ×10-2 
P2_basalnominal -6.88 52.99 24.45 -0.53 ×10-2 1.89 ×10-2 4.09 ×10-2 
P3_basalmax -7.54 69.19 25.05 -0.43 ×10-2 1.45 ×10-2 3.99 ×10-2 
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Table 5.5: Parameter values for designed LMEC controller for Parker Model 
 
[κpl  κp0  κpu] [-0.53   -0.48   -0.43] ×10-2 
[βl    β0  βu] [1.45    1.87    1.89] ×10-2 
[γl   γ0    γu] [3.99    4.09    4.25] ×10-2 
τ 6.33 
zM(s) 0.31 ×10-2 
pM(s) s2 + 11.06 ×10-2s + 0.31 ×10-2 
[θ1  θ2   θ2] [-5.10   -992.21   1038.82] ×10-2 
 
 
The robust performance of the designed LMEC controller is validated 
on a cohort of 577 virtual patients created from the Parker model (the details 
of which were presented in section 2.4). The performance of the designed 
LMEC controller on the nominal patient and on the cohort of 577 patients with 
three meal disturbances (Lehmann and Deutsch meal model described in 
section 2.3) are shown in Figures 5.5 to 5.8. The rate of maximum insulin 
infusion is set to not exceed 100mU/min (6000 mU/hr) taking into account the 
capability of modern insulin pumps.  
 
 
Figure 5.5: Performance of LMEC on nominal patient (Parker model) with 
three meal disturbances (red dash-dot line: 80 mg/dL) 



























Figure 5.7: Blood glucose concentration profiles of 577 constituted patients 
using Parker model 
 









































Figure 5.8: Insulin infusion profiles of LMEC on 577 constituted patients 
using Parker model 
 
 
With LMEC, none of the 577 patients generated from the Parker model 
enter the undesirable hyperglycemic region (>180mg/dL) and none 
experienced the dangerous hypoglycemia. Thus, all the 577 patients can be 
kept in BG range of 60~180mg/dL (with minimum and maximum BG values 
of 62.06mg/dL and 168.32mg/dL respectively). From these results, it can be 
concluded that the three parameters chosen for determination of uncertainty 
bounds are appropriate. However, steady state offset (deviation from setpoint) 
is observed in some of the patients. This may be due to insufficient integral 
action in the designed LMEC which can be improved with careful 
determination of uncertainty bounds.     
 
5.5.3 Analysis with the Fabietti Model 
The T1D patient model by Fabietti et al. (2006) contains eight patient-
dependent parameters. From these, four parameters (Txi, Ti, Ki, and Kis) are 
chosen for producing the simulated patients (circadian insulin sensitivity 
variation is kept constant at 1). These four parameters were identified as most 
important in Fabietti et al. (2006). When these parameters were varied at 3 






















levels, this resulted in a cohort of 81 virtual patients (using ±40% parameter 
variation from nominal values of the four chosen parameters). Similarly, as in 
the above models, three patients that required minimum, nominal and 
maximum basal insulin infusion are chosen. The bounds for uncertainty to 
design LMEC controller are determined from their step responses produced by 
10% reduction in their basal insulin amount. These step responses obtained are 
fitted to second order transfer functions. Then, the LMEC controller is 
designed based on the uncertainty bounds generated from three second order 
transfer function approximations. The same course of determining uncertainty 
bounds and estimating LMEC controller parameters as in section (5.5.1) are 
used in designing LMEC controller for this model. The approximated linear 
second order transfer function parameters and designed parameters for LMEC 
controller for this patient model are shown in Tables 5.6 and 5.7 respectively.  
 
Table 5.6: Parameter values of estimated second order transfer functions for 
chosen three Fabietti model patients 
 Patient (Pi) κ τ1 τ2 κp β γ 
P1_basalmin -4.59 ×10-3 3.81 3.81 -0.32 ×10-3 2.62 ×10-1 2.62 ×10-1 
P2_basalnominal -9.76 ×10-3 3.47 2.10 -1.34 ×10-3 2.88 ×10-1 4.76 ×10-1 
P3_basalmax -6.06 ×10-3 4.45 1.60 -0.85 ×10-3 2.25 ×10-1 6.27 ×10-1 
 
Table 5.7: Parameter values for designed LMEC controller for Fabietti Model 
[κpl  κp0  κpu] [-1.34 -0.85 -0.32] ×10-3 
[βl    β0  βu] [2.25    2.62    2.88] ×10-1 
[γl   γ0    γu] [2.62    4.76    6.27] ×10-1 
τ 0.87 
zM(s) 49.95 ×10-2 
pM(s) s2 + 141.36 ×10-2s + 49.95 ×10-2 
[θ1  θ2   θ2] [-67.51 -30571.56  64591.80] ×10-2 
 
The robust performance of the LMEC controller in rejection of 
disturbances is evaluated on the 81 patient cohorts that include the nominal 
patient. The embedded meal model in Fabietti et al. (2006) is used for gut 
absorption in which meal   can be defined as a mixture of sugar, starch, and 
fiber. The results of the controller performance are shown in Figures 5.9 to 
5.11. The infusion rate of insulin pump is bounded by [0, 8000] mU/hr in this 
case study assuming the future capability of insulin pumps and to show the 




Figure 5.9: Performance of LMEC on nominal patient (Fabietti model) with 






Figure 5.10: Insulin infusion profile of LMEC on nominal patient (Fabietti 
model) 








































Figure 5.11: Performance of LMEC on the 81 patient cohort generated using 
the Fabietti model (red dash-dot line: 60 mg/dL) 
 
 
From the results obtained after applying the LMEC on the 81-patient 
cohort obtained from the Fabietti model (shown in Figure 5.11), it is seen that 
all of them are maintained in BG range of 60~180mg/dL. None of the 81 
patients enter the dangerous hypoglycemic region (<3.33mmol/L=60mg/dL) 
or the postprandial hyperglycemic region (>180mg/dL) with minimum and 
maximum BG values of 67.93mg/dL and 150.32mg/dL respectively. 
 
5.6 Conclusions 
From the investigations conducted, it appears that the LMEC controller 
is a promising candidate for blood glucose control in T1D patients if frequent 
sampling (1 min interval is used in this study) of BG concentration is possible. 
LMEC is able to avoid hypoglycemia in a vast majority of virtual Type 1 
Diabetic patients. These hypoglycemic episodes can probably be circumvented 
through a careful specification of the uncertainty bounds. Steady state offset 
from the target value of 81.1mg/dL (4.5mmol/L) is also found with LMEC in 
Parker model but this may also be improved with refined uncertainty bounds. 
































Despite these drawbacks, it could be concluded that LMEC controller is 




Glycemic Control for Type 1 Diabetics using Multirate System 
Identification and Modeling Error Compensator 
 
6.1 Background 
A number of mathematical models for diabetics and several control 
algorithms for blood glucose regulation have been proposed and employed in 
the literature. Robust control algorithms were shown to cope well the inter- 
and intra-patient variability by some researchers (Parker et al., 2000 and 
Ramprasad et al., 2004b). In these studies, the inter- and intra-patient 
variabilities were represented by certain parametric uncertainty bounds. The 
LMEC controller introduced by Sun et al. (1994) is one robust controller that 
was designed to deal with bounded parametric uncertainties. The effectiveness 
of this controller for treating T1D patients was studied in Chapter 5 from 
where it appears that LMEC is a possible candidate for BG control in T1D 
patients. However, the controller depends solely on the mathematical model 
and further clinical validation would be required to test this control strategy on 
real patients. Towards this effort, it would be worthwhile to develop the 
controller based on models developed from patient data using system 
identification tools. This could pave way for a more personalized diabetic care, 
and hence it is explored here.  
 
6.2 Motivation and Objective 
For the situation in which historical data (BG and rate of insulin 
infusion amount measurements) is available from patients, the controller 
would be more effective if it is designed based on these data. Moreover, while 
frequent sampling of BG will enable better BG control, current glucose sensor 
technology is still not there.  The typical sampling time of current glucose 
sensors are 3~6 min.   Measurement of insulin infusion rates are available 
more frequently, and meal data are available on a few-hourly basis. This 
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naturally leads to a multirate data set with less frequent BG measurement, 
even less frequent meal measurement and fast insulin infusion rate 
measurement. We assume that the patient is on continuous insulin infusion. 
Developing a control strategy based on such data will benefit diabetes care. In 
this chapter, a strategy to utilize multirate patient data for designing robust 
controllers will be outlined and evaluated. 
 
6.3 Multirate System Identification and Application of Lifting Technique  
Multirate systems are periodically time varying systems and so many 
developed identification methods cannot be directly applied. Lifting technique 
is a powerful tool which converts linear periodically time varying system 
(LPTV) to linear time invariant (LTI) system to which most of the system 
identification techniques can be applied successfully. Applying the lifting 
technique to the Single Input/ Single Output (SISO) multirate system with 
input (U ) and output (Y ) which are sampled with sampling interval ( pm× ) 
and ( pn× ) respectively ( m n , :n m γ= and p = base time period, both m  
and n  are coprime) can be illustrated as follow:  
In Figure 6.1, SISO multirate system (from U  toY ) is LPTV system, 
SISO multirate lifted system (from 1 nU U  toY ) is LTI system where 
1 nU U  represent the lifted input signals, the dash-dot line represents the fast 
rate sampling (sampling interval mp ) and dash-line represents the slow rate 
sampling (sampling interval np ). The lifting the input U can be described in 
mathematical equation (6.1).  
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                                (6.1) 
      It is clear that dimension of U is n times that of U and underlying 
period of U is n times that of U again. Thus, now U and Y have the same time 
interval, np  and the lifted system becomes single rate system (lifted slow rate 
system). The details can be found in Khargonekar et al. (1985). A SISO 
multirate system can be effectively been converted into a MISO/MIMO single 
rate system. Standard system identification tools can now be applied to 
identify a model that represents the system dynamics for the slow sampling 
period. A fast rate model must then be extracted from this slow rate model.  
 
6.4 Details of the Study 
The MRID algorithm based on the lifting technique and using state 
space system identification (SSID) method would be useful in extracting the 
fast rate model from patient’s historical data. Then, an appropriately designed 
robust controller can be used to deal with unavoidable inter- and intra-patient 
variability. Previous study (Chapter 5) shows that LMEC is a good candidate 
for this purpose and we choose it to design the model based controller. LMEC 
can be implemented using the extracted fast rate model and the current glucose 
sensor sampling rate and provide frequent controller action (i.e. insulin 
infusion). Use of the fast rate LMEC is likely to lead to more effective BG 
control. The details of this algorithm will be presented in the following order: 
(1) collecting historical data (Section 6.4.1), (2) applying multirate system 
identification (Section 6.4.2) and (3) designing LMEC controller (Section 
6.4.3). The meal amount is estimated based on the scheduled and 
recommended meal amount for T1D patients (with given three meal glucose 
amounts: 20 g breakfast, 50 g lunch and 50 g dinner at 7am, 12pm, and 6pm 
respectively per day). (The measurement noise for meal measurement is not 
considered here as it is estimated.) Measurement noise on BG (sensor noise) of 
about 17% is applied throughout this study. 
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6.4.1 Collecting Patient Data 
      In the absence of real patient data, we used the data obtained by using 
the YIIP algorithm (Chapter 4) on patients generated using the model of 
Fabietti et al. (2006). Without loss of generality, data from patients or other 
model-treatment method combinations can be utilized. To be realistic, we 
collect data such that BG concentration is sampled less frequently (3 min 
sampling) while meal input (that will be transformed into glucose input from 
meal or meal ingestion profile using a filter described in Fabietti et al. (2006) 
to meal ingestion rate)  and insulin infusion rate are sampled frequently (36 
sec sampling).  
Note that BG concentration is the controlled variable (output) while the 
meal input and insulin infusion rate are the input variables. We assume that the 
“patient” has no initial hyperglycemia and receives external insulin infusion as 
recommended by the YIIP. Data is collected over a period of 17 days from a 
cohort of “patients” assuming three meal disturbances (glucose amounts: 20 g 
breakfast, 50 g lunch and 50 g dinner) per day. 
 
6.4.2 Application of Multirate System Identification 
The collected data comprises of BG measurement (one process output) 
collected at 3 min sampling interval ( pn× ) and insulin infusion rate & 
glucose input from meal that is estimated from meal input (two process inputs) 
collected at 36sec sampling interval ( pm× ), where m =1, n =5, and p =36sec. 
Thus, we have a sampling interval ratio, γ = 5. A typical illustration of the 
data can be seen in Section 4.6.2 (glucose input estimated from meal input is 
illustrated as meal ingestion profile in the figures). The two inputs are lifted 
according to Li et al. (2001) and Wang et al. (2004).  
By applying the lifting technique to the insulin infusion rate, we get the 
lifted input signals as described in eq. (6.1). After applying the lifting 
technique to the two process inputs with γ = 5, the lifted system (slow rate 
system) has ten lifted inputs and one output with the same sampling interval of 
( pn× ). A state space model of the lifted system can be expressed as follows 
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                      (6.2) 
To achieve the identifiablity of a state space model, the lifted slow-rate 
model must be controllable and observable. The lifted slow-rate system is 
controllable and observable only if the continuous-time system G is 
observable and controllable. This assumption is valid with the non-
pathological sampling interval p ; the continuous time delay τ  must be in the 
range of [0, ]p . We assume that the system time delay is within this limit in 
this study. Wang et al. (2004) proved that the lifted system can be controllable: 
(Ai, Bi) is controllable if ( , )A B is controllable and A  has no eigenvalue on the 
unit circle (the proof can be seen in Wang et al. (2004)). Here, we use the 
N4SID method (System Identification Toolbox, Matlab 2008b) to identify the 
Steady State (SS) model. 
Three ways have been proposed by Li et al. (2001) to extract the fast 
rate model from the lifted slow-rate system. Wang et al. (2004) further 
developed these methods and demonstrated how one could obtain a fast-rate 
model with sampling period p for the system with 3p hold interval and 2 p
sampling interval. Though theoretically sound, the above methods sometimes 
present numerical difficulties. An alternate approach by Lakshminarayanan 
(2000) is a practical solution to the problem. Firstly, he employs model 
reduction to the slow-rate model to obtain minimal state space form. The 
reduced-order model is produced with matching DC gain using equivalent 
steady state step response.  
The state or states to be deleted is determined using ‘balreal’ command 
in MATLAB. The ‘balreal’ command (The MathWorks, Inc. 1998) is used for 
producing a balanced realization in state space form reflecting the same 
controllable and observable properties of the individual states. The elements in 
the diagonal of the balanced realization form reflect the grammian-based 
combined controllable and observable properties of the different states.  
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One can delete those elements of the diagonal (states) with small value 
so that the most important features of the original system can be captured by 
retaining the larger values of the diagonal elements. The weak state(s) which 
are computed from ‘balreal’ command were deleted using the ‘modred’ 
command in MATLAB. The remaining model contains the most essential 
input-output characteristics of the original slow-rate system.  
The ‘modred’ command (The MathWorks, Inc. 1998) with matching 
DC gain method works as follows for the discrete-time state space model: 
Let the discrete-time state space model be 
( 1) ( ) ( )x k Ax k Bu k+ = +                                          (6.3) 
( ) ( ) ( )y k Cx k Du k= + .                                       (6.4) 
The state vector is divided into two parts, x1 (the states that are to be retained) 
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            (6.5) 
( )y k =[ ]1 2 ( ) ( )C C x k Du k+                                          (6.6) 
Then, 1x states are calculated by setting the derivative of 2x to zero and the 
reduced-order model is as follows: 
1 1
1 11 12 22 21 1 1 12 22 2( 1) [ ] ( ) [ ] ( )x k A A A A x k B A A B u k
− −+ = − + −                       (6.7) 
1 1
1 2 22 21 2 22 2( ) [ ] ( ) [ ] ( )y k C C A A x k D C A B u k
− −= − + −                            (6.8) 
Then, the fast rate model Gf with p sampling interval is extracted from 
resulting low order slow-rate discrete-time model using ‘d2d’ MATLAB 
command which can transform discrete-time model with particular sampling 
interval into discrete-time model with required sampling interval. This method 
operates in state space domain and the resulting fast-rate model is also in 
discrete-time state space form valid for sampling interval p . 
In this work, a new approach, shown in Figure 6.2, is proposed to 
obtain the fast rate model. The gain of the SS model obtained from slow rate 
identification has discrepancies due to loss of information resulting from 
lifting the system.  Thus, the best possible system gain is found using a best 
lifted insulin input and a best lifted meal input (the lifted input signals which 
have “proper response” and are best representatives of original manipulated 
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variables are chosen from the bundle of lifted input signals) by optimization 
approach that can give best fit to the output variable (here, “proper response” 
means that the signal grasps the negative sign of process gain for insulin 
model and positive sign of process gain for meal model). The nonlinear least 
squares (NLLS) fit is applied here as a quick start. The ‘lsqnonlin’ command 
in MATLAB can be used for this method; desired bounds on the optimized 
variables can be given to ensure proper values for the adjusted gain. The 
NLLS optimization method gives quick and best solution to the objective 
function. The SS model with adjusted gain is then approximated by a second 
order transfer function (SOTF). The optimization approach with direct search 
method (‘fminsearch’ function in MATLAB) is applied here. The new 
continuous SOTF with adjusted model gain and time constants can be 
converted into discrete model with sampling interval p  by using “c2d” 
command in MATLAB. This discrete model is referred to as the MRID model 
in this work. 
  
Figure 6.2: Diagram for “New MRID” (NMRID) approach 
 
The SOTF parameters are used as the initial estimates for the nonlinear 
optimization using pattern search method in MATLAB in which new 
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continuous SOTF model (referred to as NSOTF) parameters are found for the 
cost function to give the best fit to the BG output using a best lifted insulin 
input and a best lifted meal input. The pattern search engine gives the best 
possible local minimum of the objective function with specified bounds on the 
optimization variables. The obtained NSOTF model can be converted into 
discrete fast rate model with the sampling interval p  and the resulting model 
is referred to as the “New MRID” (NMRID) model in this work. Note that the 
fast rate model obtained from the NMRID procedure is employed to obtain the 
inter-sample BG estimates for each of the patients. The LMEC-MRID 
controller (to be described next) will use these estimates to determine insulin 
infusion rates at time instants where the measured BG values are not available. 
In addition, note that the parameters of NSOTF model will be used in LMEC-
MRID controller development.  
 
6.4.3 Design of Linear Modeling Error Compensator 
The LMEC controller is designed based on the BG responses of 
selected patients to changes in insulin infusion rate. LMEC is developed for 
two scenarios based on the linearized models and the uncertainty description 
derived from them. LMEC is designed based on: (1) unit step response of 
linear models (NSOTF model) obtained from MRID of 7 selected “patients” 
(LMEC-MRID I) and (2) linear models obtained from the response of the 
nonlinear models (unit step response at nominal insulin infusion rate is 
approximated by second order linear transfer function model) of 12 selected 
“patients” (including 5 more patients to the chosen 7 MRID patients) (LMEC-
MRID II). LMEC-MRID II is developed to act as performance benchmark to 
LMEC-MRID I. 
The responses of the nominal “patient” from both scenarios provide us 
the nominal model parameters. The bounds for uncertainty are determined 
from the parameters of the estimated linear second order transfer functions of 
the selected patients. The smallest and largest parameter values are defined as 
lower and upper bound. These bounds for the uncertainty (assuming that they 
represent inherent inter- and intra-patient variability) are incorporated in the 
controller design. The uncertainty bound of LMEC-MRID II was found to be 
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wider than that of LMEC-MRID I. The details of LMEC-MRID controller 
design has already been described in Section 5.3.2.  
 
6.5 MRID Results and Discussion 
Seven specific patients are chosen from the cohort of 81 patients 
(Fabietti model). These chosen patients consist of nominal patient, and the 
patients who have lowest and highest BG from each of the three groups (as 
described in Section 4.6.3). The proposed NMRID is applied to obtain the fast 
rate model from the multirate historical data (where patients were treated using 
YIIP) of the 7 patients. The parameter values of the NSOTF model for the 7 
patients are given in Table 6.1. The NSOTF model parameters are compared 
with those of actual (NL) model approximated by a second order transfer 
function and that of SOTF models. 
 
Table 6.1: Details of the NSOTF models 
Patient Model κi τi1 τi2 κm τm1 τm2 MAE 
 NL -0.16 2.77 2.77 2.08 1.29 1.29 - 
Nominal SOTF -0.07 1.27 1.27 2.47 1.16 1.16 7.21 
 NSOTF -0.09 2.89 2.89 1.64 1.91 1.91 1.51 
G1L 
(C4p3) 
NL -0.02 2.56 2.56 1.73 1.05 1.05 - 
SOTF -0.23×10-2 0.47 0.47 0.88 0.44 0.44 16.25 
NSOTF -0.026 2.45 2.45 1.29 1.24 1.24 3.56 
G1H 
(C7p7) 
NL -0.05 5 5 4.59 3.04 3.04 - 
SOTF -0.92 ×10-
2 
1.11 1.11 2.19 1.10 1.10 15.84 
NSOTF -0.03 4.64 4.64 2.44 3.41 3.41 2.45 
G2L 
(C5p3) 
NL -0.06 2.57 2.57 1.73 1.05 1.05 - 
SOTF -0.45 ×10-
2 
0.44 0.44 0.76 0.46 0.46 15.76 
NSOTF -0.09 2.50 2.50 1.36 1.43 1.43 3.50 
G2H 
(C8p4) 
NL -0.07 4.12 4.12 4.59 3.04 3.04 - 
SOTF -0.76 ×10-
2 
1.05 1.05 1.77 0.73 0.73 11.40 
NSOTF -0.10 5.39 5.39 2.27 3.12 3.12 2.14 
G3L 
(C6p3) 
NL -0.11 2.57 2.57 1.73 1.05 1.05 - 
SOTF -0.02 1.15 1.15 0.08 0.89 0.89 22.42 
NSOTF -0.23 2.95 2.84 1.57 1.74 1.74 2.69 
G3H 
(C9p7) 
NL -0.27 5 5 4.59 3.04 3.04 - 
SOTF -0.02 1.40 1.40 1.79 1.39 1.39 17.99 
NSOTF -0.18 4.87 4.87 2.43 3.40 3.40 2.63 
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The model fits using SOTF and NSOTF models are displayed in Figure 
6.3 for nominal patient and compared with the YIIP data. For the nominal 
patient, the mean absolute error (MAE) between actual data (YIIP) and 
NSOTF model prediction is 1.51mg/dL which is rather good. The gain of unit 
step response for insulin using NSOTF model is closer to that of NL model 
than that of SOTF model even though the NSOTF model gain shows a gain 
mismatch with the actual NL model (values are provided in Table 6.1). The 
model fit to the actual BG response is better with the NSOTF model than with 
the SOTF model. The NSOTF model seems more acceptable compared to the 
SOTF model. 
 
Figure 6.3: Model fit for nominal patients (solid line: SOTF model, dash-dot 
line:  NSOTF model, dotted line: actual BG response) 
 
The second chosen patient is from Class 4 (Group I) whose BG is the 
lowest in the group. The model fits to the actual BG response are compared in 
Figure 6.4 and MAE of NSOTF model is 3.56mg/dL (given in Table 6.1). The 
NSOTF model gains for both insulin and meal are much better than those 
obtained from SOTF model (values are provided in Table 6.1). The model fit 
of NSOTF model is not good as it does not match with the actual BG response 
trend at several places (e.g. between 15hr and 25hr) but is acceptable. The 
MAE of NSOTF model is higher compared to that obtained for the nominal 
patient but the difference is not significant to be of any concern.  























Figure 6.4: Model fit for a patient from Class 4, Group I (solid line: SOTF 






Figure 6.5: Model fit for a patient from Class 7, Group I (solid blue line: 
SOTF model, dash-dot black line:  NSOTF model, dotted red line: actual BG 
response) 
 





































The third chosen patient is from Class 7 (Group I) whose BG is highest 
in the group. The model fit of identified models are compared with the actual 
BG response in Figure 6.5. The MAE of NSOTF model fit is 2.45mg/dL. The 
gains of NSOTF model for insulin and meal are better than that of the SOTF 
model in terms of closeness to the gains obtained with the NL model. 
However, the gains of NSOTF model are about half of the actual response 
indicating significant mismatch to the actual BG response. Therefore, the 
response of NSOTF model is about 20mg/dL to 30mg/dL higher at the start 
(first 5 hours in Figure 6.5). These features might lead to over infusion of 
insulin and subsequently to lower BG in patients. However, this deficiency in 
the model can be compensated by bias updating.  
The fourth patient is chosen from Group II, Class 5. This patient has 
the lowest BG response in the group, and the MRID and NMRID results are 
demonstrated in Figure 6.6 for the resulting model fit. Again the NSOTF 
model gains are much better than that of the fast-rate model. The NSOTF 
model gain of insulin is higher than actual response, and that of meal is 
slightly lower than actual response (values are provided in Table 6.1). The 
NSOTF model has a MAE of 3.50 mg/dL. The estimated values for the model 
parameters indicate that use of this model in a control algorithm for computing 
insulin infusion can lead to lower insulin infusion than the actual required 
amount which may lead to hyperglycemia. This, though not optimal, is not life 
threatening in most cases. The performance of the SOTF model is not 
acceptable. 
The fifth patient is chosen from Group II, Class 8 to represent the 
patient with highest BG in this group. The MRID and NMRID results are 
presented in Figure 6.7 showing the model fit to the YIIP data. The NSOTF 
model gain for insulin is much better than the corresponding gain of the SOTF 
model. The gain for meal input is slightly better than SOTF model gain 
(values are described in Table 6.1). The NSOTF model gain for meal is lower 
than actual model gain, that for insulin is higher than actual model gain and 
time constants are greater than the actual model. These will lead to the lesser 
insulin infusion and will lead to similar effect and conclusion as in above case 
(the fourth patient). The model fit is quite good with MAE equal to 2.14mg/dL 
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for the NSOTF model. There is a mismatch of about 10mg/dL at the very start 
(0-5 hours in Figure 6.7) for the NSOTF model but the model fit for the later 
times is very acceptable. 
 
 
Figure 6.6: Model fit for a patient from Class 5, Group II (solid line: SOTF 




Figure 6.7: Model fit for a patient from Class 8, Group II (solid line: SOTF 
model, dash-dot line:  NSOTF model, dotted line: actual BG response) 






































The sixth patient is from Class 6, Group III with the lowest BG in the 
group. The MRID and NMRID model fits for this patient are shown in Figure 
6.8. The gain of insulin in the NSOTF model is about two times the true gain 
and that of meal input and is close to the actual model gain. These gains are 
much better than the gains indicated by the SOTF model (see values in Table 
6.1).  The time constant values in the NSOTF model are similar to the actual 
values. For this patient, the NSOTF model has an MAE value equal to 
2.69mg/dL. Because of much lower gain values, the SOTF model is not 
acceptable at all. (In the SOTF model identified, the time constants are also 
smaller than the true values.) Significant discrepancy is exhibited during the 
first 5 hours by the NSOTF model with higher estimated BG values than the 




Figure 6.8: Model fit for a patient from Class 6, Group III (solid line: SOTF 
model, dash-dot line:  NSOTF model, dotted line: actual BG response) 
 
 
The last (seventh) patient is from Class 9, Group III with highest BG 
values in its group. The model fits for SOTF and NSOTF are compared to the 
YIIP data in Figure 6.9. In the NSOTF model identified, the absolute value of 
gains for insulin and meal inputs are lesser than actual model gains. The 
overall model fit (for NSOTF model) exhibits a MAE value of 2.63mg/dL. 




















Significant discrepancy is exhibited during the first 5 hours by the NSOTF 
model with higher estimated BG values than the actual BG response but the 




Figure 6.9: Model fit for a patient from Class 9, Group III (solid line: SOTF 
model, dash-dot line:  NSOTF model, dotted line: actual BG response) 
 
The pattern search used for NSOTF model converges for all 7 patients 
chosen. All the above results demonstrate that the NSOTF model is better than 
the SOTF model and is closer to the actual model responses. Values of time 
constants of NSOTF model are much closer to actual model values. Likewise, 
the gain values of NSOTF models are closer to actual model gain values and 
much better than the SOTF model values. The experience with SOTF and 
NSOTF models indicate that NSOTF models can be used for controller design. 
The LMEC implementation is presented in the next section.  
 
6.6 LMEC-MRID, Results and Discussion 
LMEC-MRID implementation is described in Section 6.6.1 and the 
results are shown and discussed in Section 6.6.2. 
 



















6.6.1 LMEC-MRID Implementation 
We developed two LMEC-MRID controllers: (1) LMEC-MRID I is 
developed based on NMRID results of the 7 selected patients discussed above 
and (2) LMEC-MRID II developed based on second order transfer function 
approximation of NL model response of 12 chosen patients (7 patients 
described above and additional 5 more patients chosen randomly to obtain 
more accurate uncertainty bounds than LMEC-MRID I. LMEC-MRID II is 
designed also as benchmark controller for LMEC-MRID I and to check if 
discrepancy exists in defined uncertainty bounds by LMEC-MRID I using 
their performance comparison. 
 
LMEC-MRID I:  The NSOTF models (insulin and meal model) obtained 
from MRID are used to design the LMEC I controller (as outlined in Section 
6.4.3). The models can also help in the estimation of BG inter-sample 
measurements based on the frequently available data on meal and insulin 
inputs. Bias updating is performed at every sampling interval when the actual 
measurement is available from the BG sensor. To overcome the spikes in the 
controller outputs, a first order filter with time constant of 1 unit in simulation 
time (1hr in actual time) is applied. The initial state of the filter is set to basal 
insulin amount for each patient. The rate limiter is also applied for maximum 
input constraint and to avoid negative input. 
 
LMEC-MRID II: LMEC II (as described in section 6.4.3) is implemented 
along with the NMRID insulin and meal models which can help to estimate 
BG inter-sample measurements. The same first order filter setting is applied to 
remove input insulin infusion spikes. The same rate limiter setting as in 
LMEC-MRID I is used. 
 
6.6.2 LMEC-MRID Results and Discussion 
For the comparison LMEC-MRID performances, three patients are 
chosen (nominal patient from Group II and two patients with highest and the 
lowest BG from Group I and Group III respectively). For testing the 
disturbance rejection capability, meals containing 10 g, 50 g and 50 g of 
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carbohydrates are provided at 7 am, 12 noon and 6 pm respectively. The set 
point is one of the target values of 81mg/dL, 90mg/dL and 100mg/dL to 
investigate the proper set point to be ensure the proper BG control.  The 
disturbance rejection capability will be demonstrated at each of these three set 
points.  
 
6.6.2.1 LMEC-MRID for Group II Patients 
Firstly, the LMEC-MRID controller settings are tuned for the nominal 
patient. The input constraint (insulin infusion rate <= 4000 mU/hr) is 
implemented for ensuring safe performance. The disturbance rejection 
performance of the two LMEC-MRID controllers for nominal patient at three 
set points (81.08mg/dL, 90mg/dL & 100mg/dL) are shown in Figure 6.10, 





Figure 6.10: Performance of LMEC-MRID controllers for nominal patient 
(Group II) with set point equal to 81 mg/dL (dashed line: LMEC-MRID I, 
dash-dot line: LMEC-MRID II, solid line: tailored YIIP) 








































Figure 6.11: Performance of LMEC-MRID controllers for nominal patient 
(Group II) with set point equal to 90 mg/dL (dashed line: LMEC-MRID I, 




Figure 6.12: Performance of LMEC-MRID controllers for nominal patient 
(Group II) with set point equal to 100 mg/dL (dashed line: LMEC-MRID I, 
dash-dot line: LMEC-MRID II, solid line: tailored YIIP) 












































































As shown in Figure 6.10 to 6.12, the performances of LMEC-MRID I 
and LMEC-MRID II are comparable. The BG results are in acceptable range 
(55mg/dL~180mg/dL). The controllers take about 3 to 5 hr for the set point to 
be reached after dinner. The controller output displays a proper trend to 
counteract the meal disturbance, and the resulting BG peak values are lower 
than tailored YIIP results, with lesser total insulin infusion amount and 
without hypoglycemic (BG < 50mg/dL) events. The total insulin amounts used 
by controllers for three set points for normal day (with three meals) are 
compared in Table 6.2.  
Table 6.2: Comparison of Insulin Infusion Amount for a Group II patient 
(nominal patient) 
Set point value LMEC-MRID I LMEC-MRID II YIIP 
81 mg/dL 4.14 ×101 U 4.15 ×101 U 6.84 ×102 U 
90 mg/dL 3.95 ×101 U 3.96 ×101 U 6.84 ×102 U 
100 mg/dL 3.76 ×101 U 3.77 ×101 U 6.84 ×102 U 
 
 
The total insulin amount used by YIIP is highest and that by LMEC-
MRID I is the lowest among the three controllers. The LMEC-MRID I uses 
lesser insulin amount and has comparable performance to the LMEC-MRID II. 
The BG trajectory goes below 60mg/dL in Figure 6.10 (for set point equal to 
81mg/dL) but the patient’s BG values stay above 60mg/dL for the other two 
set point values (90mg/dL and 100mg/dL). As expected, the set point value 
100mg/dL provides the best performance (normoglycemic region of 
70mg/dL<BG<180mg/dL) compared to the other two set point values, in the 
prospect of avoiding possible hypoglycemia. According to these results, to 
avoid possible hypoglycemia, a set point value of 100mg/dL seems to be 
better.  
 
6.6.2.2 LMEC-MRID for Group I Patients 
The LMEC-MRID controller output constraint is tuned for Group I 
patients who have highest basal insulin requirements among the cohort of 
patients. The patient from Class 7 (Group I) who exhibited highest BG values 
when subject to tailored YIIP treatment is selected as a representative member 
of this group. The corresponding LMEC-MRID results are shown in Figure 




Figure 6.13: Performance of LMEC-MRID controllers for a patient from Class 
7 (Group I) with set point equal to 81 mg/dL (dashed line: LMEC-MRID I, 




Figure 6.14: Performance of LMEC-MRID controllers for a patient from Class 
7 (Group I) with set point equal to 90 mg/dL (dashed line: LMEC-MRID I, 
dash-dot line: LMEC-MRID II, solid line: tailored YIIP) 















































































Figure 6.15: Performance of LMEC-MRID controllers for a patient from Class 
7 (Group I) with set point equal to 100 mg/dL (dashed line: LMEC-MRID I, 
dash-dot line: LMEC-MRID II, solid line: tailored YIIP) 
 
The total infusion amount of insulin for each of the set points for each 
controller (LMEC-MRID I, LMEC-MRID II & YIIP) in a normal day with 
three meals is given in Table 6.3. Similarly as in the above nominal patient, 
the total insulin amount used by YIIP is highest and that by LMEC-MRID I is 
lowest among the three controllers. Likewise in the above nominal patient 
case, LMEC-MRID I has economic advantages with lesser insulin amount 
used and has comparable performance to LMEC-MRID II.  
 
Table 6.3: Comparison of Insulin Infusion Amounts for a Group I patient 
Set point value LMEC-MRID I LMEC-MRID II YIIP 
81 mg/dL 2.19 ×102 U 2.21 ×102 U 3.21 ×103 U 
90 mg/dL 2.12 ×102 U 2.13 ×102 U 3.21 ×103 U 
100 mg/dL 2.05 ×102 U 2.06 ×102 U 3.21 ×103 U 
 
The controller output is constrained so as not to exceed 20000mU/hr. 
(20U/hr.), to achieve good BG control for this group, which requires higher 
insulin amount. The process input (the controller output) has an acceptable 








































trend without any spikes and the BG profile following each meal is quite good 
with BG values above 55mg/dL. There are no hypoglycemic events. However, 
the results show that the set point is not reached between meal inputs. Similar 
to the previous case, a BG target of 100mg/dL has better performance than 
other two tested BG targets in successfully staying away from the 
hypoglycemic limit but its BG peak value hits the upper limit of 180mg/dL 
which is acceptable. The overall controller performance given the constraints 
on BG is quite satisfactory. The BG can be maintained in acceptable range 
with BG around its target value between meals though more insulin is infused 
than the tailored YIIP. 
 
6.6.2.3 LMEC-MRID for Group III patients 
The patient from Class 6 who exhibits lowest BG values in tailored 
YIIP treatment, is chosen from Group III. Patients from this group need low 
basal insulin amount when compared to other patients in the cohort. This 
patient is selected in order to test the ability of the controller in preventing 
hypoglycemic events. The results of BG regulation using the two LMEC-
MRIDs are demonstrated and compared with tailored YIIP treatment results in 
Figures 6.16 to 6.18 for three BG target values.  
The LMEC-MRID controllers are implemented with a constraint on the 
insulin infusion amount (upper limit of 2000 mU/hr). This setting satisfied the 
objective that no BG value should go under 50 mg/dL or over 180 mg/dL with 
acceptable return to set point within a 3 to 5 hr period.  
Similar to previous cases, the BG target value of 100 mg/dL is better 
for patient safety compared to the other two set point values in that it avoids 
possible hypoglycemia. The total insulin infusion amounts utilized by the 
controllers for a normal day with three meals are tabulated in Table 6.4. The 
total insulin infusion amount used by LMEC-MRID is rather less than that by 
tailored YIIP and thus LMEC-MRID is advantageous economically. Likewise 
in the above cases, the total insulin used by YIIP is the highest and that by 




Figure 6.16: Performance of LMEC-MRID controllers for a patient from Class 
6 (Group III) with set point equal to 81 mg/dL (dashed line: LMEC-MRID I, 
dash-dot line: LMEC-MRID II, solid line: tailored YIIP) 
  
 
Figure 6.17: Performance of LMEC-MRID controllers for a patient from Class 
6 (Group III) with set point equal to 90 mg/dL (dashed line: LMEC-MRID I, 
dash-dot line: LMEC-MRID II, solid line: tailored YIIP) 













































































Figure 6.18: Performance of LMEC-MRID controllers for a patient from Class 
6 (Group III) with set point equal to 100 mg/dL (dashed line: LMEC-MRID I, 
dash-dot line: LMEC-MRID II, solid line: tailored YIIP) 
 
 
Table 6.4: Comparison of Insulin Infusion Amounts for a Group III patient 
Set point value LMEC-MRID I LMEC-MRID II YIIP 
81 mg/dL 1.90 ×101 U 1.92 ×101 U 3.02 ×102 U 
90 mg/dL 1.79 ×101 U 1.80 ×101 U 3.02 ×102 U 
100 mg/dL 1.68 ×101 U 1.68 ×101 U 3.02 ×102 U 
 
 
The two LMEC-MRIDs have comparable performance. They are better 
to the tailored YIIP treatment outcomes since less insulin is used with the 
LMEC scheme. Similarly as in above cases, LMEC-MRID I outperforms 
economically with lesser insulin amount used and comparable performance to 
LMEC-MRID II.  
 
6.6.3 LMEC-MRID Validation on Parker Model Patient Cohort 
 The LMEC-MRID I controller was developed based on Fabietti model 
patient cohort. To test the effectiveness of the controller on patients generated 







































from other models, the 577 patient cohort of Parker model is chosen here. The 
disturbance rejection scenario of the controller is tested using the more 
favorable set point of 100mg/dL (5.5mmol/L).  
Firstly, the 577 patients are categorized into respective patient classes 
using MIVGTT data as mentioned in sections 4.3 and 4.4. The test data are 
pretreated and then projected onto the PCA model constructed in section 4.6.1. 
The results are shown in Figure 6.19. Categorizing the 577 patients based on 
the closeness to the nearby patient classes using t-squared values as the basis, 
the 577 patients are classified into Class 2 (86 patients out of 577 patients) – 
belonging to Group II, and Class 3 (the remaining 491 patients out of 577 
patients) – belonging to Group III. The respective LMEC-MRID I for Group II 
and Group III are administered those two patient classes (with the set 
constraints) and the results are shown in Figure 6.20 and Figure 6.21 






Figure 6.19: PCA based classification of the cohort of 577 patients obtained 
from Parker models (with data pretreatment) with 99.99% confidence interval 
 






































Figure 6.20: Performance of LMEC-MRID I for Group II controller on Class 2 







Figure 6.21: Performance of LMEC-MRID I for Group III controller on Class 
3 patients - 491 patients out of 577 Parker patients 












































































 As shown in Figure 6.20, the LMEC-MRID I for Group II controller 
can maintain BG of Class 2 patients – 86 patients almost in the range 
60~180mg/dL with the highest BG being 181.92mg/dL. The hypoglycemia 
(<60mg/dL) can be avoided successfully with the lowest BG being 
63.47mg/dL. Likewise, the result shown in Figure 6.21 reveals the fact that 
LMEC-MRID I for Group III controller (on Class 3 – 491 patients) maintained 
almost all BG values in the range of 60~180mg/dL with only one patient’s BG 
violating the range (highest BG for this patient being 192.37mg/dL) without 
hypoglycemia (with lowest BG being 69.78mg/dL). 
 These results highlight the fact that LMEC-MRID I controller could be 
a promising candidate for T1D patients managing BG within the acceptable 
range and circumventing hypoglycemia efficaciously. 
 
6.7 Conclusions 
      The proposed NMRID algorithm (NSOTF method) is quite reliable in 
providing acceptable inter-sample BG measurement estimation. The identified 
models lead to acceptable controller performance when augmented with bias 
updating mechanism, filter and constraints on the insulin infusion rate to 
controller. LMEC-MRID I is designed based on the NMRID results and 
LMEC-MRID II is designed based on the response of the NL model. Different 
LMEC-MRID settings for three groups (classified by the method proposed in 
Section 4.6.2) are proposed. The performances of LMEC-MRID I and LMEC-
MRID II for disturbance rejection at three target values are quite comparable. 
A BG target of 100 mg/dL appears to be most effective in avoiding possible 
hypoglycemic events. The LMEC-MRID controllers are seen to outperform 
tailored YIIP in keeping BG values within practical limits while using less 
insulin. The LMEC-MRID I controller performance evaluation on a cohort of 
577 patients generated with the Parker model also substantiates that LMEC-
MRID I controller is a promising candidate for blood glucose regulation 
inT1D patients. Particularly, LMEC-MRID is economically beneficial with 
lesser insulin amount used and with performance comparable to LMEC-MRID 




Conclusions and Recommendations 
 
7.1 Conclusions 
Treating T1D in a timely and effective manner is an important problem 
for which a complete, reliable solution is not yet available. In diabetic patients, 
it is crucial to keep the fasting blood glucose concentration in normoglycemic 
range (70-126mg/dL) and a postprandial BG value of under 180 mg/dL (but 
over 55mg/dL). This can be achieved using exogenous insulin infusion in a 
manner that avoids both hyperglycemia and hypoglycemia. However, the 
unavoidable inter- and intra-patient variability makes BG control very 
challenging. To obtain effective BG regulation in Type 1 diabetics, efficient 
and practically implementable control algorithms are needed. This thesis 
proposed simple, implementable and effective control algorithms that work on 
a broad range of patients. Due to the cost and safety issues that are associated 
in testing the developed algorithms on human subjects, this thesis used state-
of-the-art T1D mathematical models as virtual patients and tested the various 
control algorithms via simulations using MATLAB.     
  The rule based control algorithms that are currently practiced in ICUs 
have had significant positive effect in reducing mortality and morbidity. These 
algorithms are built based on experience and practical knowledge of the 
physicians. Among them, the YIIP is most popular. This protocol was 
modified to develop a strategy to treat a broad range of virtual T1D patients, 
and the effectiveness of this modified YIIP was studied in Chapter 3.  The 
performance of the proposed rule based control algorithm, MODYIIP, on 
cohorts of simulated virtual patents demonstrate that MODYIIP is a potential 
candidate for treating T1D patients. However, the results show that MODYIIP 
needs to be tailored to avoid possible hyperglycemia in different patients. On 
the positive side, the proposed MODYIIP was successful in avoiding 
dangerous hypoglycemia.        
To obtain effective BG regulation in T1D patients, an efficient and 
practically implementable “class-specific” control algorithm was proposed in 
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Chapter 4. In the absence of real patients, a state-of-the-art mathematical 
model that adequately simulates BG dynamics in diabetics was employed to 
develop a classification-based approach that groups “patients” into different 
classes and to demonstrate the success of tailored, “class-specific” algorithms. 
The novel approach consists of a diabetes diagnostic test (Modified 
Intravenous Glucose Tolerance Test, MIVGTT), and a multivariate statistical 
tool (Principal Component Analysis, PCA) was used for classification. Then, 
YIIP was tailored and applied to different patient classes. Applicability of this 
approach through validation on different patient models was also investigated.  
The results indicated that T1D patients can be classified into nine 
classes. Using the tailored YIIP-based treatment on a “normal day” (with three 
meals), it was observed that hypoglycemia (< 50mg/dL) can be successfully 
avoided for the entire cohort of the in silico patients without the need to 
administer any extra glucose. For any in silico patient, the MIVGTT can be 
conducted and the patient class determined. Then, the tailored YIIP for the 
particular class can be used to treat the patient. This work has investigated the 
robustness of the approach for certain intra-patient variability within the same 
patient class and obtained acceptable results. The developed algorithm appears 
to be simple, effective and practical for treating real T1D patients. Clinical 
validation of the classification approach and the control algorithm would be 
the subsequent step in this work. 
Robust controllers are other potential candidates for treatment of T1D 
patients because they can handle predefined uncertainty in model parameters. 
LMEC (linear modeling error compensator) was chosen for investigation here 
because it is a linear controller and capable of providing good performance 
with less complexity than, say, a nonlinear controller. The central idea of 
LMEC is to compensate the error arising out of parametric uncertainty by 
determining the modeling error using plant input and output signals and 
employing a linear model of known order. In addition to nominal feedback, 
another feedback loop is introduced using the modeling error and this 
feedback action is explicitly proportional to error which is induced by 
parametric uncertainty. The uncertainty bounds are determined from the 
transfer functions of virtual patients and incorporated into the controller 
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design. Effectiveness of LMEC was demonstrated on a large set of virtual 
patients embedding as much as 50% parametric uncertainty (Chapter 5). The 
results showed that LMEC is a good candidate for BG control in T1D patients 
when frequent BG sampling is possible. Clinical test of this technique is one 
possible area for future work.  
Sometimes, data on BG and insulin infusion amount can be obtained 
from medical records or from patients. These data are often available as 
multirate measurements because variable such as insulin infusion amount are 
more frequently measurable than the BG values. To handle such data and to 
develop a control strategy subsequently, the thesis proposed a LMEC-MRID 
strategy in Chapter 6. The required transfer function parameters for LMEC 
controller were estimated from multirate data using MRID. This model helped 
in the estimation of intersample BG values to be used by the LMEC 
controllers. The estimated BG values from the model were updated whenever 
an actual BG measurement became available (bias updating). The required 
uncertainty bounds were incorporated into the LMEC controller from MRID 
of patient data. This controller was named LMEC-MRID I. The benchmark 
controller, LMEC-MRID II was designed based on the linear approximation of 
original NL model. Both LMEC-MRID I & LMEC-MRID II provided similar 
control performance and were able to keep the BG values within safe limits. 
The performance validation of developed controller on different patient cohort 
also attests the acceptable performance.  This shows that the control strategy 
based on model developed from multirate patient data is a promising strategy 
for BG control in T1D patients. 
 
7.2 Recommendations for Future Works  
 In the following sections, the recommended future works are 
summarized. 
  
7.2.1 Classification Methods   
The classification of patient classes using PCA with data pretreatment 
is simple and quite effective. However, more efficient classification methods 
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such as Dynamic PCA (DPCA) would be worth exploring. Patient data from 
MIVGTT is dynamic in nature so that DPCA would be the right choice to 
handle the classification problem. Other classification approaches such as 
Qualitative Trend Analysis can also be employed. 
 
7.2.2 Incorporation of Recursive Identification Scheme into LMEC-MRID 
The existing bias updating scheme suggested for our LMEC-MRID 
implementation is simple suggesting that the performance would be better if a 
more efficient updating scheme can be implemented.  Moreover, the intra-
patient variability that exists in T1D patients owing to different situations such 
as changing insulin sensitivity, stress and lifestyle should be identified as 
parametric variations and utilized in the LMEC-MRID algorithm. Recursive 
identification methods could be employed to handle such parameter variations 
leading to an adaptive-LMEC algorithm.  
 
7.2.3 Association of Exercise and Other Effects into Modeling 
The exercise effect cannot be neglected in real patients and has been 
taken into account by some researchers (e.g. Roy and Parker, 2006). These 
models need to be modified to handle the intensity and duration of exercise. 
Anxiety and stress can also affect BG dynamics. Anxiety and stress are known 
to cause hypertension which is correlated to hyperglycemia (Mancia, 2007). 
These issues should be dealt with in modeling of diabetics, and applied control 
strategies for BG regulation in T1D patients should also take these aspects into 
consideration. More comprehensive models of diabetes need to be developed 
and employed in artificial closed loop pancreas systems. 
 
7.2.4 Nonlinear Control Strategy 
The LMEC is effective in avoiding severe hypoglycemia for given 
uncertainty bounds. If an adequate nonlinear model is available, one could try 
employing a nonlinear modeling error compensator based on the fundamental 
nonlinear model and the uncertainty associated with its parameters. This 
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extension of MEC to biomedical process control can be an excellent avenue 
for research. 
 
7.2.5 Diabetes Control in ICU patients  
     Critically ill patients or patients in ICU experience stress induced 
hyperglycemia even if they do not have any past history of diabetes. Other 
factors such as presence of hypertension, cortisone and pancreatic disease may 
also results in hyperglycemia. From the extensive literature review, it is clear 
that intensive insulin therapy (IIT) can reduce morbidity, mortality and 
duration of patients stay in ICU. According to Leuven study, an IIT that 
maintains BG in the 80-110 mg/dL range can reduce: ICU mortality by 42%, 
bloodstream infections, the incidence of acute renal failure, the need for 
prolonged ventilatory support, and the duration of ICU stay (Goldberg et al., 
2004). Many IIP protocols have been developed for glycemic control in ICU - 
some protocols have been developed for medical ICU (MICU) and some 
others have been proposed for use in surgical ICUs (SICU). These protocols 
are currently based on physicians’ expertise and experience; however, they can 
be further optimized and personalized to provide tight BG control. Avoiding 
hypoglycemia is the primary intention in ICU patients. Developing a protocol 
that can avoid hypoglycemia, provide tight glycemic control for the different 
conditions of patients with minimal physician intervention, and is easy to use 
by ICU nursing staff would be worth the effort. Developing a patient model 
that takes into account conditions such as hypertension, corticosteroid, and 
administration through enteral or parenteral routes would be worthwhile 
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Yale Insulin Infusion Protocol & Lam et al.’s Meal Model 
 
 
A.1 Yale Insulin Infusion Protocol 
The following Yale Insulin Infusion Protocol (YIIP) is taken from 
Goldberg et al. (2004). 
This insulin infusion protocol is intended for use in hyperglycemic 
adult patients in an ICU setting, but is not specifically tailored for those 
individuals with diabetic emergencies, such as diabetic ketoacidosis (DKA) or 
hyperglycemic hyperosmolar states (HHS). 
When these diagnoses are being considered, or if BG>=500 mg/dL, an 
MD should be consulted for specific orders. Also, please notify an MD if the 
response to the insulin infusion is unusual or unexpected, of if any situation 
arises that is not adequately addressed by these guidelines.  
 
Initiating an Insulin Infusion 
1) Insulin Infusion: Mix 1U Regular Human Insulin per 1cc 0.9%NaCl. 
Administer via infusion pump (in increments of 0.5U/hr). 
2) Priming: Flush 50cc of insulin through all IV tubing before infusion 
begins (to saturate the insulin binding sites in the tubing). 
3) Target Blood Glucose (BG) Levels: 100-139mg/dL 
4) Bolus & Initial Infusion Rate: Divide initial BG level by 100, then 
round to nearest 0.5U for bolus AND initial infusion rate. 
5) Examples:     
a. Initial BG = 325mg/dL: 325 ÷ 100 = 3.25, round to 3.5: IV 
bolus 3.5U + start infusion @ 3.5U/hr. 
b. Initial BG = 174mg/dL: 174 ÷ 100 = 1.74, round to 1.5: IV 
bolus 1.5U + start infusion @ 1.5U/hr. 
144 
 
Blood Glucose (BG) Monitoring 
1) Check BG hourly until stable (3 consecutive values within target 
range). In hypotensive patients, capillary blood glucose (i.e., 
fingersticks) may be inaccurate and obtaining the blood sample from 
an indwelling vascular catheter is acceptable. 
2) Then check BG 2 hourly; once stable for 12-24 hours, BG checks can 
then be spaced 4 hourly IF: 
a. no significant change in clinical condition AND  
b. no significant change in nutritional intake. 
3) If any of the following occur, consider the temporary resumption of 
hourly BG monitoring, until BG is stable again (2-3 consecutive BG 
values within target range): 
a. any change in insulin infusion rate (i.e., BG out of target range) 
b. significant changes in clinical condition 
c. initiation or cessation of pressor or steroid therapy 
d. initiation or cessation of renal replacement therapy 
(hemodialysis, CVVH, etc.) 
e. initiation, cessation, or rate change of nutritional support (TPN, 
PPN, tube feedings, etc.) 
 
Changing the Insulin Infusion Rate 
 
If BG < 50 mg/dL 
D/C^ Insulin Infusion:  Give 1 amp (25 g) D50 IV; recheck BG at every 15 
min. (When BG >= 100 mg/dL, wait 1 hour, then restart insulin infusion 
at 50% of original rate) 
  
If BG 50-74 mg/dL 
D/C^ Insulin Infusion: If symptomatic (or unable to assess), give 1 amp (25 g) 
D50 IV: recheck BG at every 15min.  
                                    If asymptomatic, give ½ Amp (12.5 g) D50 IV or 8 
ounces juice; recheck BG at every 15-30 min.  
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(When BG >= 100 mg/dL, wait 1 hour, then restart insulin infusion at 
75% of original rate) 
 
If BG >= 75 mg/dL 
Step 1: Determine the CURRENT BG LEVEL – identifies a COLUMN in the 
table below. 
Step 2: Determine the RATE OF CHANGE from the prior BG level – 
identifies a CELL in the table – Then move right for INSTRUCTIONS: 
[Note: If the last BG was measured 2-4 hours before the current BG, 
calculate the hourly rate of change. Example: If the BG at 2PM was 150 
mg/dL and the BG at 4PM (now) 120 mg/dL, the total change over 2 













 BG↑ by > 50 mg/dL/hr BG↑ 




BG↑ by > 25 
mg/dL/hr 
 








BG↓ by > 1-
25 mg/dL/hr 










BG↓ by > 1-
25 mg/dL/hr 
BG↓ by > 1-
50 mg/dL/hr 








BG↓ by > 1-
25mg/dL/hr 
BG↓ by > 26-
50 mg/dL/hr 
BG↓ by > 
51-75 
mg/dL/hr 
BG↓ by > 
76-100 
mg/dL/hr 
↓ INFUSION by 
“∆” 
BG↓ by > 25 
mg/dL/hr 
See below† 
BG↓ by > 50  
mg/dL/hr 
 
BG↓ by > 75 
mg/dL/hr 




↓ INFUSION by 
“2∆” 
 
† D/C^ INSULIN INFUSION: Check BG at every 30 min, when BG ≥ 100 




*CHANGES IN INFUSION RATE (“∆”) are determined by the current rate: 
Current Rate (U/hr) ∆ = Rate Change (U/hr) 
2∆ = 2× Rate 
Change (U/hr) 
<3.0 0.5 1 
3.0 – 6.0 1 2 
6.5 – 9.5 1.5 3 
10 – 14.5 2 4 
15 – 19.5 3 6 
20 – 24.5 4 8 




A.2 Lam et al.’s Meal Model 
The associated meal model for Bergman T1D patient model that is 
developed by Lam et al. (2002) is described here. 
This meal model is designed originally for OGTT and is modelled by 
the lognormal distribution function as in equation (B.1). The glucose input is 
modelled to be smooth, continuously differentiable and to ensure zero initial 
conditions. This function can be easily implemented and is physiologically 
representative. 
𝑃(𝑡)  =  𝑃𝑚𝑒𝑥𝑝(−𝑎(𝑙𝑛(𝑏𝑡) − 𝑐)2)                                               (B.1) 
where, 
 𝑃𝑚 = the peak value of exogenous glucose absorption rate 
𝑎, 𝑏 and 𝑐  = constants which determine the slopes and curvature of exogenous 
                     glucose absorption rate 
The model parameter values can be defined to represent the different 
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